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RESUMO 
 
A encefalopatia hepática é uma síndrome neuropsiquiátrica decorrente de 
distúrbios cerebrais induzidos por doenças do fígado. A encefalopatia 
hepática crónica é associada com  a cirrose e é caracterizada por uma fibrose 
progressiva do parênquima do fígado, o que conduz à hipertensão portal e à 
deterioração da função do fígado. A alteração na síntese e secreção de ácidos 
e de outros componentes biliares contribui para a disbiose intestinal, a qual, 
juntamente com a hipertensão portal, altera a permeabilidade intestinal e, 
consequentemente, promove a translocação bacterial. A hipertensão portal, 
em associação com um comprometido processo de detoxificação, permite que 
toxinas, entre as quais amónia, passem para a circulação sistémica. O 
aumento de amónia em circulação, denominado hiperamonémia, é uma das 
principais características da encefalopatia hepática. Os probióticos surgem 
assim como uma possível forma de tratamento para a encefalopatia hepática, 
uma vez que estes previnem a translocação bacterial  e reduzem a produção e 
consequente absorção de amónia. A encefalopatia hepática é também 
acompanhada por um défice cerebral de creatina e, assim, a suplementação 
oral com creatina emerge também como um potencial tratamento. Esta tese é 
baseada em estudos preliminares para avaliar o papel do VSL#3®, um cocktail 
probiótico, e da suplementação oral com creatina na neuroprotecção, em 
ratos com o ducto colédoco obstruído, um modelo de doença do fígado 
crónica. Para isso, a técnica de espectroscopia de protões por ressonância 
magnética foi utilizada, permitindo a análise do metabolismo cerebral, dado 
que a encefalopatia hepática induz alterações na osmorregulação, 
neurotransmissão e metabolismos antioxidante e energético cerebrais. Os 
nossos resultados foram promissores, demonstrando a viabilidade dos 
estudos e permitindo-nos melhorar o protocolo experimental para estudos 
futuros.  
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ABSTRACT 
 
Hepatic encephalopathy is a neuropsychiatric syndrome that stems from liver 
disease-induced cerebral disorders. Chronic hepatic encephalopathy is 
associated with cirrhosis and is characterized by a progressive fibrosis of the 
liver parenchyma, which leads to portal hypertension and deterioration of 
liver function. Altered synthesis and secretion of bile acids and other biliary 
components contributes to gut dysbiosis that, along with portal 
hypertension, alters intestinal permeability and consequently promotes 
bacterial translocation. Portal hypertension, along with a defective 
detoxification process, allows intestinal toxins, namely ammonia, to bypass 
the liver into systemic circulation. The increased circulating ammonia, 
named hyperammonemia, is one of the main features of hepatic 
encephalopathy. Probiotics emerge, therefore, as a possible treatment 
strategy for hepatic encephalopathy, since they prevent bacterial 
translocation and reduce the production and consequent absorption of 
ammonia. Furthermore, hepatic encephalopathy is accompanied by a cerebral 
creatine deficiency and, in that sense, creatine oral supplementation may 
also arise as a treatment approach. This thesis is based on preliminary studies 
designed to assess the neuroprotective roles of VSL#3®, a probiotic cocktail, 
and creatine oral supplementation in bile duct-ligated rats, a model of 
chronic liver disease. For that purpose, proton magnetic resonance 
spectroscopy was performed longitudinally and the cerebral metabolism 
analyzed, given that hepatic encephalopathy induces alterations in cerebral 
osmoregulation, neurotransmission, and antioxidant and energy 
metabolisms. Our results were promising, showing the feasibility of the 
studies and opening the way to improve our experimental protocol for future 
studies. 
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CHAPTER 1 
Basics of the Hepatic Encephalopathy (HE) 
and Treatment Strategies 
 
 
1.1. Introduction to HE 
 
Liver failure and its concomitant liver-dependent processes 
impairment often result in a wide range of harmful events, which affect 
several systems and associated functions. Among them, one can distinguish 
liver disease-induced cerebral disorders that collectively constitute the 
neuropsychiatric syndrome termed hepatic encephalopathy (HE) (Morgan et 
al., 2007). 
According to the type of hepatic abnormality, the encephalopathy can 
be classified in type A, associated with acute liver failure (ALF) and resulting 
from severe inflammatory and/or necrotic liver disease of rapid onset; type B, 
associated with portacaval shunting in the absence of parenchymal liver 
disease, which is normally a consequence of congenital disorders; and type C, 
associated with chronic liver disease (CLD), i.e. cirrhosis, due to alcoholism, 
viral infection, biliary obstruction, drugs or toxins. Cirrhosis is the end stage 
of a wide range of liver diseases and is characterized by progressive fibrosis of 
the liver parenchyma, which leads to portal hypertension and deterioration of 
liver function. Portal hypertension compromises the detoxification process 
by allowing intestinal toxins to bypass the liver into systemic circulation 
through the high portal pressure-stimulated opening of embryonic venous 
channels (Butterworth et al., 2009). Cirrhosis is associated with a variety of 
complications, such as ascites and variceal hemorrhage, that together with an 
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increased susceptibility to infections in general, account for a high morbidity 
and mortality (Schuppan and Afdhal, 2008). 
While an abrupt loss of hepatic function occurs in ALF and leads to a 
rapid deterioration in consciousness and high mortality rate, the chronic 
form of HE progresses slowly, accompanied principally by neuropsychiatric 
manifestations consisting of personality disorders, altered mood, increased 
irritability, altered changes in sleep/wake cycles, decline in intellectual 
capacity and abnormal muscle tone (Jones and Weissenborn, 1997), 
collectively causing a serious impact in the health-related quality of life of 
the patients. 
Based on the characteristics of the neurologic manifestations in CLD, 
HE has been subdivided into minimal or covert, associated with subtle 
cognitive impairments of attention, response inhibition and executive 
function detectable only by neuropsychological and neurophysiological 
testing; and overt. The latter is further separated according to the duration of 
the neurologic manifestations into episodic, occurring over a short time span 
and fluctuating in severity; and persistent as a chronic clinical condition of 
cognitive deficits that affects social and occupational functioning. 
Additionally, overt HE is routinely graded according to the West Haven 
criteria, which assesses the severity of disease taking into account the 
changes of consciousness, intellectual function and behavior (Ferenci et al., 
2002). The classification ranges from 1 to 4 and is linked, respectively, to 
mild, moderate, severe and coma status of disease. 
Different types of liver disease, i.e. ALF and CLD, have different 
etiologies, lead to different cerebral and neurological alterations and, thus, to 
different forms of HE. Besides, HE can affect both the developing and adult 
brain in different ways. Expectedly, each mentioned situation is mediated by 
dissimilar pathophysiological mechanisms and, so, requires different 
therapeutic approaches. This thesis will be focused on the chronic hepatic 
encephalopathy (CHE, type C), thus enabling long-term progressive disease 
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studies in an adult animal model submitted to a persisting and prolonged 
hepatic insult. 
 
1.1.1. Pathogenesis of HE 
 
The pathogenesis of HE is not completely understood yet, but it seems 
to be a result of a complicated interplay of multiple factors and abnormalities 
involving gut-derived nitrogenous compounds, specifically ammonia. In fact, 
the gut is the main source of ammonia production (Solga, 2003) through both 
intestinal urease-producing bacteria, being urease a catalytic enzyme that 
hydrolyses urea into carbon dioxide and ammonia; and phosphate-activated 
glutaminase (PAG) activity in the enterocytes, which catalyzes the 
deamination of glutamine (Gln) to glutamate (Glu) and yields ammonia as an 
end product. Additionally, amino acid metabolism is also a pathway of 
ammonia production. 
Under normal circumstances, ammonia is detoxified in the liver 
through the urea cycle, which is located near the portal vessels as first line of 
defense and converts ammonia to urea prior to renal excretion, thus 
maintaining circulating concentrations of ammonia within 35 – 65 µM (Rose, 
2014). In patients with cirrhosis, the metabolic capacity of the liver is 
exceeded giving rise to an increase of circulating ammonia, named 
hyperammonemia, which is a major and commonly observed feature of HE. 
Glutamine synthetase (GS), which is present in muscle, kidney, liver and 
brain, tries to compensate for this dysfunction by catalyzing the 
condensation of Glu and the surplus ammonia, forming Gln (Figure 1). 
Besides the neurotoxic effects that arise from brain tissue exposure to 
ammonia, some of which are related to Gln, other cirrhosis-induced noxious 
events, such as systemic inflammation, seem to contribute and/or exacerbate 
the manifestations of HE. 
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Several interactive metabolic and signaling axes exist and 
physiologically connect gut, liver, muscle and brain through 
neurotransmitters, bile acids, short chain fatty acids, choline degradation 
products, aromatic acids and phenolics, inflammatory mediated lipids and 
endocannabinoids (Holmes et al., 2012), supporting the notion of HE as a 
multifactorial disease, but also offering up a series of potential targets for 
therapeutic interventions. 
 
 
Figure 1 - Inter-organ trafficking of ammonia in healthy individuals and in patients 
with cirrhosis. Under healthy conditions, ammonia is mainly detoxified in the liver, 
but also in the muscle and, to a lesser extent, in brain. In patients with cirrhosis, the 
metabolic capacity of the liver is exceeded, resulting in an increase in circulating 
ammonia. Under these circumstances, the surplus ammonia is mainly detoxified in 
muscle, but also in brain and, to a lesser extent, in the liver, with the production of 
glutamine (Gln); this is in turn broken down to ammonia by phosphate-activated 
glutaminase (PAG) in enterocytes or else excreted by kidneys as ammonia. Figure 
taken from Morgan et al. (2007). 
 
1.1.1.1. In the Brain 
 
The blood-brain barrier (BBB) is the largest physical and metabolic 
barrier between periphery and the brain and helps regulate brain homeostasis 
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and protects it from endogenous and exogenous toxins arising from systemic 
circulation. However, BBB is easily crossed by ammonia, either by diffusion of 
its gaseous form (NH3), or through potassium (K+) channels crossing of its 
ionic form (ammonium, NH!! ). At physiological pH, more than 98% of 
ammonia is present as NH!!  (Rose, 2014). Under hyperammonemia, the 
incorporation of blood-borne ammonia, in addition to the one derived from 
endogenous reactions, into the amide position of Gln is largely confined to 
astrocytes and represents the main route of central nervous system (CNS) 
ammonia removal (Brusilow et al., 2010). 
Accordingly, in the setting of HE and unlike most neurodegenerative 
diseases, astrocytes rather than neurons primarily exhibit critical 
morphological and functional alterations, with both astrocyte swelling and 
Alzheimer type II astrocytosis being the hallmarks of the disease. However, 
functional derangements of astrocytes can lead to neuronal abnormalities, 
since astrocytes are highly regulated cells, which communicate directly with 
neurons and participate in neurotransmitter processing, regulation of the 
ionic milieu in the brain and substrate provision for neurons. Notably, the 
Gln-Glu cycle, whose role is to recycle the Glu that has been released from 
neurons, thus avoiding neuron excitotoxicity, is performed between GS, 
specifically found in astrocytes, and PAG, primarily found in neurons (Rama 
Rao et al., 2012). Furthermore, astrocytes’ feet line BBB and uptake of 
substances from the blood into the brain requires transastrocytic transport. 
Thus, systemic-derived ammonia entering the brain is readily converted to 
Gln in astrocytes, confirmed by the increased brain levels of Gln that have 
been reported, which seem to correlate better with the severity of HE than 
plasma ammonia concentration (Laubenberger et al., 1997). 
Gln is a neutral and electrophysiological inert but osmotically active 
amino acid, and although it is generally believed to be innocuous, it is indeed 
the precursor of several deleterious effects induced by ammonia in the CNS in 
HE, namely astrocyte swelling and consequent cerebral edema. Although 
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there is not a consensus on how Gln exerts its toxicity on astrocytes, one can 
mention three well-accepted hypotheses to explain it. 
According to the Trojan Horse Hypothesis (Albrecht and Norenberg, 
2006), Gln enters astrocyte mitochondria via the Small Neutral Aminoacid 
Transporter (SNAT), a process potentiated by ammonia, being hydrolyzed by 
PAG, which is located in the inner mitochondrial membrane, yielding Glu and 
ammonia. The generation of high levels of ammonia can lead to an excessive 
production of reactive oxygen species (ROS) and, consequently, induction of 
the mitochondrial permeability transition (MPT), resulting in mitochondrial 
dysfunction. The ensuing mitochondrial dysfunction leads to the impairment 
of the sodium (Na+) pump, resulting in the influx of Na+ and obliged water 
(Norenberg et al., 2005). In support of this theory, the blockage of the Gln 
transport into mitochondria and its hydrolysis by, respectively, L-histidine 
and 6-diazo-5-oxo-L-norleucine (DON) markedly attenuated the noxious 
effects of ammonia. Accordingly, cyclosporin A (CsA), an inhibitor of MTP, 
and the use o antioxidants abrogated the ammonia-induced astrocyte 
swelling, which suggests MTP and oxidative stress as key factors in its cause. 
However, the presence of PAG in astrocytes in vivo is still not clear. 
The increased brain levels of Gln followed by a decrease of myo-
inositol (Ins) represent a common pattern observed in cirrhotic patients with 
HE using the proton magnetic resonance spectroscopy (1H MRS) technique 
(Shawcross et al., 2004; Cudalbu, 2013). This pattern can be explained based 
on the Glutamine Hypothesis, which proposes that the accumulation of Gln 
in astrocytes causes changes in brain osmolarity resulting in cell swelling and 
brain edema. The activation of osmoregulatory mechanisms induces the 
release of osmolytes, such as Ins, taurine (Tau) and choline-containing 
compounds (total choline, tCho) (Brusilow et al., 2010). However, the 
cerebral edema is usually less pronounced in CLD patients compared to the 
ALF group, implicating not only the several-fold increase of brain Gln 
concentrations but also the duration of this increase on the development of 
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brain edema. In an initial phase, a very pronounced osmotic stress occurs in 
the astrocytes due to increased Gln synthesis in these cells, similarly to what 
follows acute hyperammonemia. However, with time in the chronically 
hyperammonemic patients, there is a gradual compensation as reflected by a 
diminution in other osmolytes. This compensation is accompanied by 
increased water in the extracellular space; however, astrocyte swelling 
remains even in chronic hyperammonemia, as a consequence of an 
incomplete osmoregulatory effect. 
Under normal conditions, a significant proportion of newly 
synthesized Gln rapidly leaves astrocytes, both by diffusion and by specific 
Gln transporters (mainly the N/A-system transporter SNAT3 and SNAT5, 
formerly known, respectively, as SN1 and SN2). The Transporter Hypothesis 
postulates that the increased Gln synthesis coupled with a partial 
suppression of SNAT3 and SNAT5-mediated efflux of Gln from astrocytes 
observed in acute hyperammonemic rat studies (Kanamori and Ross, 2005; 
Desjardins et al., 2012), result in an accumulation of Gln in the astrocytic 
compartment, which originates an osmotic stress. However, since astrocytes 
are the major source of extracellular Gln in brain, a commensurate reduction 
of brain extracellular levels of Gln does not occur as expected according to 
this hypothesis. 
Since all the hypotheses have its advantages and drawbacks, a 
combination of mechanisms seem to be behind the action of Gln in the CNS. 
It is, however, noteworthy that in the absence of irreversible cerebral edema, 
HE symptoms in adults are largely reversible when ammonia returns to 
normal levels, a fact that, apparently, can only be explained by the glutamine 
hypothesis. 
Other clinical observations possibly involved in the pathogenesis of HE 
are decreased serum levels of branched-chain amino acids and increased 
levels of aromatic amino acids. The principal neuroinhibitory 
neurotransmitter, γ-aminobutyric acid (GABA), is also increased in the 
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cerebral spinal fluid of patients with encephalopathy. Other toxins identified 
in the CNS include increased levels of endogenous benzodiazepine-like 
compounds, ROS, nitric oxide (NO) and inflammatory cytokines, and a 
depletion of endogenous antioxidants is also observed. 
 
1.1.1.2. In the Gut 
 
Although the recognition of the relationship between hepatic coma 
and the absorption of nitrogenous substances from the intestine emerged in 
the middle of the last century (Phillips et al., 1952), it took until the last few 
years for the symbiotic relationship between the mammalian host and its gut 
microbial community, i.e. gut microbiota, to gain a tremendous research 
interest. 
The composition and activity of the gut microbiota codevelop with the 
host continually through lifetime, varies topographical and temporally, and is 
influenced by extrinsic factors, with particular bacterial species occupying 
specific niches in the body habitat or being associated with particular growth 
or maturation phases of the host. The microbiota of infants is seeded at birth 
and seems to be influenced by a variety of factors, such as method of delivery, 
breast or bottle-feeding and epigenetics. Subsequent modulation of the 
microbial landscape is then driven by a series of complex and dynamic 
interactions throughout life, including diet, life-style, disease, antibiotic use 
and the mammalian host genome that together shape a series of unique 
habitats within and between individuals. 
The intimate coevolution of the microbiota with their mammalian 
hosts has resulted in an interlocked mutually beneficial relationship with the 
microbiota controlling or contributing to essential host functions such as 
harvesting energy, shaping the host immune system, metabolism of 
xenobiotics (compounds of nonhost origin that enter the gut with the diet or 
are produced by the microbiota), and metabolic signaling, and, thus, 
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collectively providing critical biosynthetic pathways that significantly extend 
host metabolic capacity. The developmental trajectory of the microbiome, 
incorporating the microbes and their collective genomes, modulates the 
metabolic phenotype of the host and greatly influences host biochemistry 
and susceptibility to disease. The changing relationships between the 
microbiome and host biochemistry during development also offers a series of 
interventional windows that can be aligned with disease prevention during 
early life and treatment of specific conditions later in life (Nicholson et al., 
2012). 
A close anatomic and functional relationship between liver and gut 
originate the gut-liver axis, with the intestine supplying the major part of the 
blood to the liver through the portal vein, which carries various toxic 
compounds such as bacteria and their derivatives, including ammonia, to be 
filtrated. In return, liver secretes bile acids to the intestine and modulates its 
activity. 
Under healthy conditions, microbiota is predominantly constituted by 
gram-negative bacteria and anaerobes, which are estimated to be 100 to 1000 
times more than aerobic ones. Anaerobic species have a critical role in 
producing short-chain fatty acids that reduce colonic inflammation and 
nourish colonocytes, limiting the growth and colonization of pathogen 
bacteria through the competition for nutrients, adhesion to intestinal mucosa 
and production of anti-bacterial peptides (Bajaj et al., 2014). 
Any disruption in the amount and composition of gut microbiota can 
result in a disturbance to the intestinal homeostasis and lead to gut dysbiosis, 
where potentially hostile microbes proliferate at the expense of normal 
commensal and symbiont microbes. In the context of cirrhosis, altered 
synthesis and secretion of bile acids and other biliary components together 
with abnormal intestinal motility may explain this imbalance. 
Bacterial overgrowth interferes with intestinal permeability through 
the increased synthesis of NO, which leads to an impaired intestinal structure 
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due to oxidative stress, and the high concentration of toxic acetaldehyde 
produced via metabolism of ethanol (Imani Fooladi et al., 2013). Additionally, 
portal hypertension influences intestinal permeability by decreasing the 
thickness of mucosa, one of the constituents of intestinal wall. An impaired 
intestinal permeability allows bacterial translocation, i.e. the migration of 
bacteria and/or their products from the intestinal lumen to mesenteric 
lymph. As a consequence of intestinal bacterial overgrowth, impaired host 
defenses, and/or disruption of the gut mucosal barrier, some gram-negative 
species belonged to enterobacteriaceae, enterococci and streptococci 
families, especially some strains of Escherichia coli adhere to the mucosal 
surface of intestinal walls and pass across them efficiently. 
Thus, a release of bacterial endotoxins occurs, mainly consisting of 
lipopolysaccharides (LPS), together with flagellin, peptidoglycan and 
microbial nucleic acids, collectively termed as pathogen-associated molecular 
patterns (PAMPs). Through the portal blood flow draining the 
gastrointestinal tract, intestinal bacteria and bacterial products, such as LPS, 
reach the liver for filtration; the increase in PAMPs and accumulation of 
metabolites in the liver can cause liver harm. This happens through the 
recognition of PAMPs by Toll-like receptors (TLRs) expressed on the kupffer 
cells, the resident macrophages of the liver, thus modulating kupffer cells’ 
activity and cytokine production and causing inflammation stimulation and 
oxidative damage in the liver (Figure 2.a.). Proinflammatory cytokines such 
as interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6 modulate the 
cerebral effect of ammonia and there is mounting evidence that systemic 
inflammation results in exacerbation of the symptoms of HE in cirrhotic 
patients across all grades of HE (Tranah et al., 2013). Thus, proinflammatory 
mechanisms may act synergistically with ammonia in producing cognitive 
impairment of varying degree. 
Therefore, gut microbiota represents a more recently discovered target 
on the treatment of HE, by the manipulation of its composition to benefit 
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host health. A better understanding of how interindividual variation in 
microbial composition contribute to disease risk or health sustainability may 
point to new therapeutic interventions and disease prevention strategies 
(Holmes et al., 2012). 
 
Figure 2 – a. Schematic illustration of multifarious mechanisms involved in liver 
diseases and b. probiotic influences on them. The intestinal mucosa functions as the 
local defense barrier that helps to prevent the invasion and systemic spread of 
bacteria and endotoxins, which are mostly LPS from the cell walls of gram-negative 
bacteria. However, under certain conditions, intestinal barrier function can be 
impaired or overwhelmed, allowing bacteria and endotoxins within the 
gastrointestinal tract to reach systemic organs and tissues, a process termed 
bacterial translocation. The liver is an important site for bacterial phagocytosis and 
clearance as it contains the largest population of tissue macrophages. Activated 
kupffer cells exposed to pro-inflammatory mediators, such as LPS or other bacterial 
products, are the major source of inflammatory mediators including pro-
inflammatory cytokines, chemokines and reactive oxygen/nitrogen species, which 
contribute to liver injury. Through pattern recognition receptors, including TLRs, 
the innate immune system recognizes conserved PAMPs. The beneficial effect of 
probiotics relies in the reduction of pathogenic bacteria through the competitive 
inhibition and in the improvement of nutritional status of gut epithelium, thus 
preventing bacterial translocation. BT: bacterial translocation; NO: nitric oxide; 
ROS: reactive oxygen species; PAMPs: pathogen-associated molecular patterns. 
Figure modified from Imani Fooladi et al. (2013). 
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1.2. Treatment Options for HE 
 
To date, the available HE treatment options are limited to correct or 
remove precipitating causes, dietary changes and pharmacologic approaches. 
Surgical techniques and liver transplant arise as the ultimate and, if possible, 
avoidable ways of treatment, taking into account their invasiveness and, in 
the case of liver transplant, also the lack of organs donation. 
The prompt identification and correction of precipitating factors can 
prevent the deterioration of hepatocellular function, emerging as a beneficial 
approach for most episodes of HE, since it is potentially caused by reversible 
factors, such as infection, diuretic overdose and hemorrhage. 
In addition to HE, malnutrition is a common complication of cirrhosis, 
marked by loss of skeletal mass. As it was mentioned above muscle tissue 
plays an important role in removing the circulating ammonia and, in that 
context, optimizing nutritional status is crucial. The recent consensus 
achieved by the members of the International Society for Hepatic 
Encephalopathy and Nitrogen Metabolism (ISHEN) provides several 
guidelines on the nutritional management of HE in patients with cirrhosis 
(Amodio et al., 2013). Generally, one can detach the timing of caloric 
ingestion, with the advise of taking small, frequent meals, evenly distributed 
throughout the day, in order to avoid the utilization of amino acids for 
glucose (Glc) production since it depletes tissue protein stores and produces 
ammonia. Furthermore, the ingestion of proteins is recommended, with 
vegetable proteins being preferred over meat and fish ones. Among other 
reasons, vegetable protein diets contain significantly more dietary fiber than 
isonitrogenous meat protein ones, and a high fiber diet may be beneficial for 
HE patients by decreasing gastrointestinal transit time, reducing intraluminal 
pH and increasing fecal ammonia excretion. The mechanism of action and 
efficacy of additional dietary supplements, namely probiotics and creatine 
(Cr), which are the motivations of this thesis, will be further discussed below. 
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Although some general rules on the dietary modulation can be 
established, mainly based on its efficacy on a few studies and on previous 
disease knowledge, the guidance of dietary changes should be directed to 
each individual, based on the assessment of body composition, in order to 
unveil the specific needs of each patient, that can, for instance, range from 
depletion to weight gain. 
Few of the pharmacological agents used to treat HE, at the present 
time, have been subject to rigorous evaluation by way of placebo-controlled 
trials. Additionally, most of the studies lacked standard definitions and 
grading scales of HE and included small samples sizes. Despite these 
limitations, the treatment of HE is generally aimed at decreasing and/or 
modifying the production and absorption of intestinal toxins, mainly 
ammonia, either by stimulating its detoxification, adsorbing it or altering the 
bacterial flora. Furthermore, oral supplementation of branched-chain amino 
acids and micronutrients, as well as pharmacological normalization of the 
neurotransmission system can resolve several abnormalities and symptoms 
during the disease. Non-absorbable disaccharides and non-absorbable or 
poorly absorbed antibiotics are the most widely used agents. However, 
treatment with non-absorbable disaccharides, most commonly lactulose, is 
limited by side effects and narrow therapeutic window and, consequently, the 
compliance with the treatment may be suboptimal. On the other hand, non-
absorbable or poorly absorbed antibiotics, especially rifaximin, have fewer 
side effects, but costs, at least in the short-term, are high and long-term 
safety is undetermined. Hence, potentially new agents, namely probiotics, are 
emerging and their efficacy being tested. 
 
1.2.1. Prebiotics, Probiotics and Synbiotics 
 
Prebiotics, probiotics and synbiotics are functional food components 
that modulate gut microbiota to benefit host well-being and health. A meta- 
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-analysis performed by Shukla and colleagues and the only comparing the 
effects of gut flora modulation using prebiotics, probiotics and synbiotics on 
minimal HE showed that, although a significant improvement stemmed from 
all of the treatments, lactulose, a non-absorbable disaccharide and classified 
by some as prebiotic, appeared to have the most beneficial effect, followed 
closely by probiotics and synbiotics (Shukla et al., 2011). 
Prebiotics are non-digestible food ingredients that are selectively 
metabolized by colonic bacteria that have the capacity to improve health, 
thus allowing specific changes in both the composition and/or activity of the 
gastrointestinal microbiota (Manning and Gibson, 2004). Currently, non-
absorbable disaccharides, especially lactulose, represent the most widely 
used prebiotics on the treatment of HE. 
The beneficial effect exerted by the non-absorbable disaccharides is 
due to a reduction of the ammonia intestinal production by coliform bacteria 
and of its consequent absorption, mainly through a cathartic effect and 
gastrointestinal tract acidification. However, side effects like diarrhea, 
abdominal bloating and low Na+ levels are common. As its name implies, 
these disaccharides are not absorbed in the small intestine, passing intact 
into the large intestine where they are metabolized by colonic bacteria. 
Among non-absorbable disaccharides one can distinguish lactulose (β-
galactosidofructose) and lactilol (β-galactosidosorbitol) as standard 
pharmacological agents for the treatment of HE, with the former being the 
first line pharmacological treatment for this condition (Blei and Cordoba, 
2001). 
Als-Nielsen and colleagues performed a systematic review on the 
efficacy of non-absorbable disaccharides for HE, where they included 
randomized controlled trials that assessed lactulose or lactilol versus placebo, 
no treatment, or antibiotics, for a median treatment duration of 15 days, in 
cirrhotic patients with overt HE. Although low quality trials were included, 
from the high quality ones they were able to conclude that they “did not find 
	   15	  
sufficient evidence to determine whether lactulose or lactilol have a 
significant beneficial effect in patients with hepatic encephalopathy” (Als-
Nielsen et al., 2004b). More recently, Gluud and colleagues were able to 
update this review by adding randomized controlled trials assessing the effect 
of lactulose versus no intervention, which were performed in the meantime, 
proving the beneficial effects of lactulose and lactilol on the improvement of 
manifestations of HE and prevention of clinically overt HE and thereby 
supporting the use of non-absorbable disaccharides in clinical practice 
(Gluud et al., 2013b). 
Probiotics are live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host. Many probiotic 
species are used for the production of fermented food and have been 
consumed safely as part of these foods for millennia. Furthermore, many 
bifidobacteria and lactobacilli species are normal, nonpathogenic inhabitants 
of the human gastrointestinal tract, oral cavity, skin, and, in women, of the 
vagina (Sanders, 2003). 
Besides improving host health, probiotics must be safe, persist on the 
gastrointestinal tract long enough to elicit an effect and should be amenable 
to and remain viable during the production and storage processes. Probiotics 
exert their beneficial effects in the treatment of HE at multiple levels, namely 
by decreasing the production and absorption of ammonia and increasing the 
hepatic clearance of ammonia and other toxins. While the first effect is 
achieved through a reduction of bacterial urease activity through the 
competitive inhibition, the second stems from a decrease in both intestinal 
pH and permeability through the improvement of nutritional status of gut 
epithelium. The latter effect is originated by a diminution of both 
inflammation and oxidative stress in hepatocytes (Figure 2.b.). Additionally, 
there are various probiotic strains that can help remove several nitrogenous 
waste products and uremic toxins from the gastrointestinal tract and the 
blood stream, which are utilized as nutrients for microbes’ growth. Thereby, 
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microbial load increases, thus generating a greater potential for diffusion of 
the uremic toxins from systemic circulation through the intestinal walls into 
the gut. Collectively, probiotics consumption lowers circulating ammonia 
concentration and attenuates its consequent deleterious effects. 
Presently, the clinical use of probiotics for patients with HE can not be 
recommended mainly because of two reasons: current evidence suggest that 
most trials evaluating the role of probiotics in the treatment of HE are of not 
high quality and have high risk of both systematic and random errors (McGee 
et al., 2011); and the concerns about the probiotics treatment safety with 
immunocompromised individuals and patients exhibiting pre-existing 
digestive lesions/syndromes, who may, in theory, be more vulnerable to the 
translocation of bacteria from the gut lumen. However, clinical studies have 
indicated already that a wild spectrum of probiotics can be consumed safely 
in patients with various gastrointestinal diseases (Chermesh and Eliakim, 
2006) and immunocompromised conditions (Homayouni Rad et al., 2013). In 
fact, there is evidence that probiotics represent a safer, better tolerated (Ding 
et al., 2014) and perhaps less expensive therapy, in comparison with 
disaccharides and antibiotics, and thus more appropriated for long-term use 
in CHE. It is, however, noteworthy, that experimentation on the efficacy and 
safety of probiotics is limited compared with the available literature on 
lactulose and rifaximin. Additionally, the types and dosages of probiotics 
used in trials have been variable (Shukla et al., 2014), which may critically 
influence the results from study to study, since properties and effective 
actions of each probiotic are unique. Therefore, and taking into account one 
of the aims of this thesis, one must focus on the probiotic strains that 
collectively compose the VSL#3®.  
VSL#3® is a probiotic cocktail comprised of eight different lyophilized 
bacterial cultures, among which four belong to the genus Lactobacillus, three 
belong to the genus Bifidobacterium and one is a strain of Streptococcus 
thermophilus. The strains present in VSL#3® are non-pathogenic, non-               
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-toxigenic bacteria and their survival and growth in the environment is not 
favorite, since they are asporogenes, facultative anaerobic bacteria, with high 
nutritional requirements. Additionally, by being gram-positive organisms, 
these bacteria do not produce endotoxins. 
Lactobacillus acidophilus is a normal inhabitant of the human 
gastrointestinal tract and has a safe history of use in foods in fermented milks 
and probiotics since 1950. Lactobacillus plantarum is a normal inhabitant of 
plant material, which is routinely isolated from silage of fermented 
vegetables and has a safe history of use in food since 1965. Lactobacillus 
paracasei was firstly isolated from cheddar cheese and has a safe history of 
use in food as a dairy starter culture since 1970. Lactobacillus delbrueckii 
subsp. bulgaricus was firstly isolated from cheddar cheese and has a safe 
history of use in food as a dairy started culture since 1970. Bifidobacterium 
infantis has a safe history of use in fermented milks and infant formulas since 
1980 (Mountzouris et al., 2002). Bifidobacterium longum was firstly isolated 
from the intestines of a human adult and has been commercialized as a 
probiotic in yoghurts and dietary supplements for more than fifteen years. 
Bifidobacterium breve is a normal inhabitant of the human gastrointestinal 
tract and has a safe history use in fermented milks and infant formula since 
1980 (Sanders, 2003). Streptococcus thermophilus is the principal component 
of the natural flora of yoghurt and certain cheese types (Brigidi et al., 2003) 
and has a documented history of use in food since 1930. 
So far, some studies in humans have assessed the efficacy of VSL#3® on 
the treatment of HE. It has been shown that VSL#3® is effective in treating 
patients to prevent development of a first episode of HE, i.e. primary 
prophylaxis, and in preventing its recurrence in patients who had a previous 
episode of HE, i.e. secondary prophylaxis. To obtain the former result, Lunia 
and colleagues performed a single-center, prospective, open-labeled 
randomized trial in 160 cirrhotic patients and compared the efficacy of 
VSL#3® with placebo during a three-month period, through the evaluation of 
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hepatic and intestinal function (Lunia et al., 2014). Concerning the proven 
efficacy of VSL#3® on the secondary prophylaxis, Dhiman and colleagues 
performed a double blind, randomized, placebo controlled study during a six-
month period and assessed the hospitalizations for overall complications of 
liver cirrhosis and for those involving HE, hepatic function and blood 
cytokine levels (Dhiman, 2013). 
On the other hand, although the efficacy of VSL#3® on the treatment 
of HE has not ever been tested in animal models, studies on certain beneficial 
mechanisms of action of VSL#3® in rats have been performed. Sánchez and 
colleagues demonstrated that VSL#3® probiotic treatment decreases bacterial 
translocation, the pro-inflammatory state, with reduction of serum TNF-α 
and ascites formation in rats with carbon tetrachloride-induced cirrhosis. For 
that, a group of adult male Sprague-Dawley rats drank an approximate dose 
of 12.8 billion bacteria per kilogram of rat body weight with the treatment 
beginning at six weeks after the cirrhosis induction and during an average of 
8.6 weeks. The results were compared with two other groups treated with 
water: one composed of cirrhotic and another of non-cirrhotic rats (control) 
(Sanchez et al., 2014). In addition, Chang and colleagues showed that VSL#3® 
exerts a protective effect on intestinal permeability using a wild type rat 
model of acute alcoholic intestinal injury. For that, they assessed the 
expression of proteins that compose tight junctions, which connect gut 
epithelial cells and so prevent the bacterial translocation, and plasma levels 
of endotoxins and TNF-α. The comparison was made between a control group 
of adult rats, a group to which only alcohol was given and others treated 
either with VSL#3®, Gln, or the combination of both, or placebo, being Gln 
the traditional agent used on the treatment of such pathology (Chang et al., 
2013). Another study with bile duct-ligated (BDL) adult male Wistar rats, a 
model of CLD and the one that will be used on this thesis, showed that 
VSL#3® prevents endothelial dysfunction, an abnormality caused by portal 
hypertension and consequent oxidative stress and to which bacterial 
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translocation seems to play a role. In that sense, a group of rats was treated 
with VSL#3® in a daily dose of 50 billion bacteria per kilogram of rat body 
weight, since three weeks before the cirrhosis induction and during seven 
weeks. This group was compared with a sham group receiving VSL#3® and 
also with another two control groups: a BDL and a sham groups, both 
receiving vehicle (Rashid et al., 2014). 
Synbiotics, i.e. the mixture of pre- and one or more probiotic strains, 
also appear as a promisor option for the management of HE. Knowing the 
beneficial effects of both prebiotics, especially lactulose, and probiotics, a 
combination of them may provide a synergistic or additive effect towards 
removal of ammonia and other nitrogenous wastes from the gut and blood 
stream (Sekhar et al., 2013). 
 
1.2.2. Non-absorbable Antibiotics 
 
By altering the gastrointestinal flora through a reduction of the 
urease-producing bacteria, certain oral antibiotics can decrease the 
production and, consequently, the absorption of ammonia. In addition to 
patients that are symptomatic on non-absorbable disaccharides and due to its 
extreme sweet taste, non-absorbable disaccharides can not be well tolerated 
in the longer-term giving rise to antibiotics used as second agents on the 
treatment of HE. As with antibiotics in general, the disadvantage of its 
prolonged use is the emergence of multiresistant organisms. One solution 
might be the administration of antibiotics and probiotics alternately 
(Lighthouse et al., 2004). 
The proven efficacy and safety of rifaximin, a synthetic and also poorly 
absorbed antibiotic used as first line therapy in several countries in Europe, 
Asia, Africa and Latin America, make it the actual option with the highest 
benefit–risk ratio for treating HE (Morgan et al., 2007). However, its costs 
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remain an important concern, limiting its long-term and/or larger patient 
populations use. 
The meta-analysis on non-absorbable disaccharides for the treatment 
of HE included five trials testing the efficacy of rifaximin versus lactulose or 
lactilol in cirrhotic patients with overt HE, over a median treatment duration 
of fifteen days (Als-Nielsen et al., 2004b). Rifaximin administration resulted 
in a beneficial effect on HE manifestations, which was further confirmed by 
two randomized controlled trials in cirrhotic patients with minimal HE for a 
rifaximin treatment lasting eight weeks (Bajaj et al., 2011; Sidhu et al., 2011). 
Furthermore, a large high quality randomized controlled trial evaluated the 
longer-term effect of rifaximin administration versus placebo, during six 
months (Bass et al., 2010; Sanyal et al., 2011). It included cirrhotic patients 
who had at least two episodes of overt HE during the previous six months and 
91% of the patients received lactulose at baseline. Compared with placebo, 
rifaximin reduced the risk of HE and improved the quality of life, supporting 
its use in clinical practice and raising the interest on a treatment modality 
combining lactulose and rifaximin. 
Although not widely used for the treatment of HE mainly due to the 
limited studies performed, discouraging previous results and/or adverse 
effects found, one can also designate other antibiotic types: neomycin, 
ribostamycin, vancomycin and paromomycin (aminoglycosides), 
metronidazole and nitazoxanide. 
 
1.2.3. Creatine (Cr) 
 
The system comprising Cr, phosphocreatine (PCr) and creatine kinase 
(CK) is essential to maintain the high energy levels necessary for CNS 
development and functions, since its principal roles are the regeneration and 
cell buffering of adenosine triphosphate (ATP). In addition, Cr is important 
for dendritic and axonal elongation (growth cone migration), Na+-K+-ATPase 
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activity, neurotransmitters release, maintenance of membrane potential, 
calcium (Ca2+) homeostasis, and restoration of ion gradients in CNS. There is 
also evidence for Cr to act as a true neurotransmitter (Almeida et al., 2006), 
antioxidant (Sestili et al., 2011) and one of the main CNS osmolytes (Bothwell 
et al., 2002). 
The potential neuroprotective effect of Cr in HE has been studied 
using an in vitro model of cultured embryonic rat brain cell aggregates 
exposed to NH!!. Braissant and colleagues were able to demonstrate that 
ammonia exposure to developing brain cells impairs axonal and dendritic 
growth, accompanied by a Cr deficiency. The adding of Cr to the culture 
medium partially prevented the impairment of axonal growth in a glial-
dependent manner (Braissant et al., 2002). 
Although ammonia-induced neurotoxicity was not observed after 
axonal maturation supporting the fact that ammonia does not induce 
irreversible damage to CNS in adults, Cr has also been found decreased in 
adult BDL rats (see below), possible due to an osmoregulatory mechanism. In 
addition, Cr has been shown to exert protective effects in various 
degenerative processes, including Huntington and Parkinson diseases, 
amyotrophic lateral sclerosis or cerebral ischemia (Klein and Ferrante, 2007).  
Under physiological conditions in adults, BBB is low permeable for Cr 
bloodstream taking up, partly because astrocytes do not express SLC6A8, the 
Cr specific transporter. However, astrocytic SLC6A8 expression seems to be 
induced by NH!!  exposure (Braissant et al., 2008). Thus, oral Cr 
supplementation should be considered as a therapeutic option for HE. 
 
1.2.4. Branched-Chain Amino Acids 
 
The low plasmatic levels of branched-chain amino acids (valine, 
leucine and isoleucine) observed in patients with advanced liver disease 
raised the interest in their oral supplementation as a potential treatment for 
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HE. Under hyperammonemic circumstances, the degradation of branched-
chain amino acids is promoted by the stimulation of Gln synthesis, which 
induces the cerebral afflux of aromatic amino acids, since there is a 
competition between branched-chain amino acids and aromatic amino acids 
for the transporter at the BBB. Consequently, a disturbance of 
neurotransmitter synthesis may occur. Besides the reversal of the deleterious 
events that may arise from its deficiency, supplements with branched-chain 
amino acids potentiate several cerebral, metabolic and nutritional positive 
effects that may benefit patients with HE (Tajiri and Shimizu, 2013). In fact, 
Gluud and colleagues concluded in a systematic review with meta-analyses of 
randomized controlled trials in cirrhotic patients with recurrent minimal or 
overt HE that oral branched-chain amino acids supplements improve 
manifestations of HE but have no effect on mortality, through comparison 
with control supplements or placebo (Gluud et al., 2013a). 
 
1.2.5. Supplementation of Micronutrients 
 
Zinc deficiency is frequently observed in patients with CLD and may 
explain a number of abnormalities that have been reported in that condition, 
namely immune dysfunction. Oral zinc supplementation arises therefore as a 
solution to correct zinc deficiency, which is associated with an impaired 
nitrogen metabolism by decreasing the activity of urea cycle enzymes in the 
liver and GS in muscle that are zinc-dependent. Chavez-Tapia and colleagues 
performed a meta-analysis on the use of oral zinc in the treatment of 
cirrhotic patients with different stages of HE and found a neuropsychological 
melioration, without evident improvement on HE or HE-related quality of life 
(Chavez-Tapia et al., 2013). 
Furthermore, low circulating levels of Na+ can alter brain function both 
directly or by interacting with the mechanisms causing HE, and is recognized 
as a risk factor for the development of HE. Moreover, and not directly 
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implicated in the pathophysiology of HE, deficiencies of the water-soluble 
vitamins, particularly thiamine, are associated with a wide range of 
neuropsychiatric symptoms. In addition, changes in circulating levels of Ca2+, 
magnesium and iron can produce changes in the mental function, ranging 
from confusion to coma or secondary dementia. Therefore, the levels of these 
micronutrients must be controlled and orally supplemented, if needed 
(Amodio et al., 2013). 
 
1.2.6. L-Ornithine Phenylacetate, Sodium Benzoate 
and Sodium Phenylacetate 
 
L-ornithine phenylacetate, sodium benzoate and sodium 
phenylacetate are used in the treatment of urea cycle enzyme deficiencies 
since they metabolically fix ammonia by utilizing alternative pathways for 
waste nitrogen excretion. While L-ornithine acts as a substrate for Gln 
synthesis from ammonia in skeletal muscle, phenylacetate and benzoate 
conjugate, respectively, with Gln and glycine, and both end products are 
excreted by kidneys. Thereby, these therapies may not be appropriated for 
patients with significant fluid retention or kidney dysfunction because of the 
kidneys’ role on excretion and the significant dose-dependent Na+ content in 
the case of sodium benzoate and sodium phenylacetate. 
A recent study with BDL rats provided new insights into the 
mechanism of action of L-ornithine phenylacetate by showing that this 
compound reduces plasma ammonia by modulating muscle GS and gut PAG 
activities, which seem to be, respectively, decreased and increased in 
hyperammonemia (Jover-Cobos et al., 2014). Additionally, in consequence of 
the ammonia lowering, L-ornithine phenylacetate reduced the systemic and 
brain inflammation in BDL rats (Balasubramaniyan et al., 2012; Wright et al., 
2012). Although it seems to be safe when administered to patients with 
	  24	  
compensated and decompensated cirrhosis (Jover-Cobos et al., 2013), there is 
a lack of clinical trials to prove its efficacy on HE. 
A study with eight cirrhotic patients with chronic stable HE 
demonstrated that, although sodium benzoate may be superior to sodium 
phenylacetate when added to a diet restriction and neomycin or lactulose, the 
combination of both agents might be better than either agent used alone. A 
non-controlled trial evaluating the efficacy and safety of a six-month 
administration of sodium benzoate in eighteen patients with CHE have 
shown improvements in their condition, although the score used to assess HE 
is no longer in use (Misel et al., 2013). Adverse effects like gastrointestinal 
symptoms are among the most reported during sodium benzoate utilization. 
 
1.2.7. L-Ornithine-L-Aspartate 
 
Lowering of ammonia through the stimulation of Gln synthesis and 
ureagenesis, the key metabolic pathways for ammonia detoxification, is the 
mechanism of action of L-Ornithine-L-Aspartate, a salt of the amino acids 
ornithine and aspartate (Asp). With a low incidence of side effects except for 
mild gastrointestinal disturbances, the administration of L-Ornithine-L-
Aspartate has resulted in a more prominent improvement of HE and 
reduction of serum ammonia compared to placebo/no-intervention in 
cirrhotic patients with minimal and overt HE (Bai et al., 2013). 
 
1.2.8. L-Carnitine 
 
Therrien and colleagues performed a study on portacaval-shunted rats, 
where a protective effect of L-carnitine on ammonia-precipitated 
encephalopathy was evident (Therrien et al., 1997). 
Up to date, almost all the randomized controlled trials evaluating the 
efficacy and safety of acetyl-L-carnitine, the acetylated form of L-carnitine, 
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on the treatment of HE were carried in a single center, in Italy, and an 
improvement in the quality of life, anxiety, depression (Malaguarnera et al., 
2011) and cognitive functions (Malaguarnera et al., 2008) accompanied by a 
reduction in serum ammonia levels have been observed in cirrhotic patients 
with minimal HE without significant side effects. 
The therapeutic effect of L-carnitine on HE is achieved by acting at 
several levels, namely through the activation of metabotropic glutamate 
receptors (mGluR) at the level of brain ammonia uptake and/or mitochondrial 
energy metabolism (Jiang et al., 2013). 
 
1.2.9. Pharmacological Modulation of Glutamate 
(Glu), γ-Aminobutyric Acid (GABA), Benzodiazepine, 
Dopamine and Endocannabinoid Receptors 
 
The increase of cerebral ammonia levels enhances glutamatergic 
activity and, consequently, overstimulation of N-methyl-D-aspartate 
(NMDA) receptors, leading to excitotoxicity and cellular pathways alteration. 
Some reports suggest that activation of the Glu – NO – cyclic 
guanosine monophosphate (cGMP) pathway associated to NMDA receptors 
plays a role in learning. The impaired cognitive function and learning 
observed in patients with liver disease and in animal models of CLD or 
hyperammonemia seems to be related with alterations in the mentioned 
pathway, which result in the extracellular decrease of cGMP. Sildenafil, a 
pharmacological inhibitor of the cGMP-degrading phosphodiesterase that 
crosses BBB, exerts a protective effect on the brain possibly by modulating 
the extracellular concentration of cGMP and has shown to restore learning 
ability in rats with CLD or hyperammonemia without liver failure (Rodrigo et 
al., 2006). 
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Additionally, memantine, a non-competitive NMDA receptor 
antagonist improved hyperammonemia-induced encephalopathy in 
portacaval-shunted rats (Vogels et al., 1997). 
Furthermore, ammonia exposure of the brain tissue can result in 
alterations of other glutamatergic receptors such as mGluR, and other 
neurotransmission systems like the activation of GABA receptors, and 
reduction in dopaminergic neurotransmission. In that sense, pharmacological 
modulators of these receptors have been emerging as potential therapies. 
The psychomotor slowing and hypokinesia observed in patients with 
HE seem to be related with alterations in glutamatergic neurotransmission in 
the substantia nigra pars reticulata and the blockage of mGluR1 at this site by 
antagonists have normalized the motor activity in portacaval shunt-induced 
CLD in rats (Cauli et al., 2006). 
Through a review on the randomized controlled trials, Als-Nielsen and 
colleagues evaluated the efficacy and safety of flumazenil, a benzodiazepine 
antagonist, in cirrhotic patients with HE. In spite of not having effects 
neither on recovery nor on mortality and to possibly be associated with 
adverse events, flumazenil had a significant short-term improvement on HE 
and a highly favorable prognosis in comparison with placebo (Als-Nielsen et 
al., 2004a). 
Patients with HE may present with extrapyramidal symptoms and 
changes in basal ganglia, symptoms also associated with Parkinson disease. 
Concerning the improvement of extrapyramidal symptoms, dopamine 
receptors agonist, such as bromocriptine and levodopa may represent a 
treatment option. However, a recent review on randomized trials evaluating 
the beneficial and harmful effects of bromocriptine and levodopa versus 
placebo or no intervention in patients with HE found no arguments to refute 
or recommend the use of dopamine agents on the treatment of HE, since 
more randomized placebo-controlled clinical trials without risks of 
systematic and random errors are needed (Junker et al., 2014). 
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1.2.10. Molecular Adsorbent Recirculating System 
(MARS) and Spherical Carbon Adsorbent (AST-120) 
 
The selective removal of toxic substances accumulated in the body as a 
consequence of liver-dependent processes impairment should prevent their 
deleterious effects and improve the clinical outcome of patients with HE. 
The molecular adsorbent recirculating system (MARS) consists of 
elements for extracorporeal renal replacement techniques, i.e. hemodialysis 
and hemofiltration, as well as adsorption using albumin to remove both 
albumin-bound and water-solved toxins (e.g. ammonia) from plasma. A 
randomized controlled trial with seventy cirrhotic patients with grade 3 or 4 
of HE assessed the efficacy, safety and tolerability of standard medical 
therapy with or without MARS device additional use and showed a good 
tolerability, with no unexpected adverse events and an earlier and more 
frequent improvement of severe HE (Hassanein et al., 2007). 
The spherical carbon adsorbent (AST-120) is an oral adsorbent 
constituted by engineered activated carbon microspheres with high 
nonspecific adsorptive surface area that pass intact through the 
gastrointestinal tract, where they adsorb to toxins and mediators of 
inflammation, including ammonia. A phase 2, multicenter, randomized study 
with 47 cirrhotic patients with grade 1 or 2 of HE showed that AST-120 is as 
effective as lactulose for treatment of low-grade HE and better tolerated 
(Pockros et al., 2009). Furthermore, AST-120 has proved to lower arterial 
plasma ammonia levels, attenuate brain edema and normalize locomotor 
activity in adult BDL Sprague-Dawley rats (Bosoi et al., 2011). 	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1.3. Non-Invasive Techniques to Study HE in 
Chronic Liver Disease (CLD) 
 
Based on the previous knowledge about the pathogenic events behind 
HE, assessing the alterations on the concentration of certain brain 
metabolites represents a task of extreme importance on the diagnosis, study 
of the disease progression and treatment efficacy evaluation. 
Therefore, 1H MRS arises as a powerful technique that allows an in vivo 
and non-invasive study of HE. This technique, in conjugation with a high 
magnetic field, allows the tracking of approximately twenty metabolites from 
different brain regions, from which Gln, tCho, Tau, Ins and Cr, involved in 
osmoregulation; Asp and Glu, involved in neurotransmission; alanine (Ala), 
lactate (Lac), Cr and PCr, involved in energy metabolism; and glutathione 
(GSH), an antioxidant, are mandatory for the characterization of brain 
metabolism in HE. 
 
 
1.4. Current State of Research on Chronic Hepatic 
Encephalopathy (CHE) 
 
1.4.1. Importance of in vivo Studies 
 
Cudalbu and colleagues assessed recently and for the first time the in 
vivo and longitudinal progression of HE in BDL rats using H!  MRS, Proton 
Spectroscopic Imaging (1H MRSI) and diffusion tensor imaging (DTI) 
(Cudalbu et al., 2012). Although few studies using biochemical methods were 
performed ex-vivo (brain extracts) or on cultured cells (astrocytes or 
neurons), studies on in vivo models of CLD are preferred since they reproduce 
better the disease-induced effects on the human organism. The primordial 
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motivation of experimentation in animal models in general has to do with its 
posterior application for the benefit of human beings. 
At the present time, an optimal model of CHE does not exist. However, 
the surgically obstruction of the common bile duct induces a reproducible 
model of biliary cirrhosis in rats, which was approved as an animal model of 
type C HE by members of the ISHEN (Butterworth et al., 2009). The bile duct 
ligation induces liver failure and BDL rats develop jaundice, portal 
hypertension, portal-systemic-shunting, bacterial translocation and immune 
system dysfunction, and show decreased locomotor activities. 
 
1.4.2. Previous Results on Bile Duct-Ligated (BDL) 
Rats 
 
1.4.2.1. Brain Edema and Osmolytes 
 
There is only one recent in vivo study in BDL Sprague-Dawley rats 
using H!  MRS and performed on a 7T magnetic resonance system, at 4, 5 and 
6 weeks after the surgery. Changes in very few metabolites (i.e. Gln, Ins, 
tCho, Glu and N-acetylaspartate (NAA) were shown at late time points 
(Chavarria et al., 2013). 
Another study in BDL Sprague-Dawley rats has shown a significant 
increase of brain water content, an indicator of brain edema, at six weeks 
after the bile duct obstruction. The brain edema appearance was correlated to 
a prominent increase of blood ammonia and systemic oxidative stress levels 
but not with any BBB extravasion (Bosoi et al., 2012). 
As it was already mentioned, HE-related learning and memory 
abnormalities have been associated with disturbances in different 
neurotransmitter pathways. Behavioral studies have been undertaken to 
explore the spatial and temporal structure of behavior, as well as to 
investigate the cognitive function in BDL rats. The open-field task in adult 
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female Wistar rats showed altered spatio-temporal locomotor and 
exploratory activities, characterized by a decrease in the total distance 
traveled, increased immobility time and smaller total number of rearings 
(Leke et al., 2012). In addition, an object recognition task conducted in adult 
male Wistar rats demonstrated an impairment of short-term memory for 
recognition and unaffected long-term memory (Leke et al., 2013). 
 
1.4.2.2. Preliminary Studies: Research done in 
CIBM/LIFMET 
 
Several in vivo and longitudinal studies have taken place in Centre 
d’Imagerie Biomédicale (CIBM) and Laboratory of Metabolic Imaging 
(LIFMET) (Cudalbu et al., 2012; Braissant et al., 2013; Cudalbu, 2013), 
allowing the chronological assessment of metabolic concentrations in some 
brain regions known to be linked to cognitive impairments in patients and 
animals with CHE. For that, H!  MRS at a 9.4T main magnetic field have been 
performed in adult BDL rats during eight weeks after biliary cirrhosis-induced 
operation. 
On hippocampus, a gradual increase of Gln has been observed, 
reaching more than two-fold increase at eight weeks. On the other hand, 
other metabolites were found to be decreased: firstly, Ins (~30-35%), 
followed, respectively, by Tau (~10-20%) and tCho (~30-40%). However, the 
sum of the osmolytes remained roughly constant over time. Furthermore, Cr 
decreased gradually, reaching ~13-20% at 8 weeks, as well as the brain 
neurotransmitters Glu, Asp and GABA (~10-30%) and the brain antioxidants 
ascorbate (Asc) and GSH (~9-15%). Brain histology by immunofluorescence 
assessed the morphology of the astrocytes and the water channels expression 
at the eighth week post bile-duct ligation and showed swollen astrocytes and 
a slight increase of the water channels expression. Furthermore, plasma 
ammonia levels were measured and found increased. 
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Based on these results, the authors were able to conclude that an 
osmotic regulation is triggered by the Gln increase, resulting in a reduction of 
other osmolytes. However, this balance attempting seems to be not 
completely satisfactory, since a low-grade edema is still formed, with 
evidence based on astrocyte swelling. The increased expression of water 
channels contributes to an increased BBB permeability, which can be also 
related to cerebral edema. 
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CHAPTER 2 
Introduction to Proton Magnetic Resonance 
Spectroscopy (1H MRS) 
 
This chapter was generally based on information taken from de Graaf (2008), 
Kunz (2010) and Lanz (2012). 
 
2.1. Nuclear Magnetic Resonance (NMR) 
 
Nuclear magnetic resonance (NMR) is the study of magnetic properties 
and energies of nuclei. 
 
2.1.1.  Nuclear Spin and Magnetic Moment 
 
 The nucleus is a dense region composed of protons and neutrons, 
which have a half-integer spin equal to ½ . The number of protons and 
neutrons, as well as the nuclear spin quantum number, I, which represents 
the vectorial combination of the spins of protons and neutrons characterize 
the nucleus. 
Although classical physics is incapable of describing the quantum 
mechanical spin, it can be used to create a familiar frame of reference in 
which the existence of a spin angular momentum can be visualized. The 
nuclear spin, I, represents the rotation of the nucleus around its own axis at a 
constant velocity. This motion is described by an angular momentum vector L. Since the rotating nucleus carries an electrical charge, conferred by 
protons, a current loop is created that, consequently, generates a magnetic 
field characterized by the nuclear magnetic moment or magnetic dipole 
moment, µμ. As a result, the nucleus can be thought of as a minute bar 
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magnet. The angular momentum is directly proportional to the magnetic 
moment through the expression: 
   
 µμ = γL (2.1) 
   
where γ is the gyromagnetic ratio of the nucleus. 
In quantum mechanics, the intrinsic angular momentum of 
elementary particles and nuclei is quantized and its projection in the z 
direction, L!, and amplitude, L , are given, respectively, by: 
   
 L! = h2π m (2.2) 
   
 L = h2π ∙ I ∙ I+ 1  (2.3) 
   
where h is Planck’s constant and m is the magnetic quantum number that 
specifies the direction of angular momentum and can have 2I+ 1 values, 
given by: 
   
 m = I, I− 1, I− 2,… ,−I (2.4) 
   
Due to the intricate interactions between nucleons, i.e. the 
components of the nucleus, the nuclear spin quantum number I  cannot 
simply be calculated by summation of the nuclear individual components. 
However, by using the mass number A, which represents the total number of 
nucleons, and the atomic number or protons number Z of a given atom, I can 
be deduced from the following rules:  
1. For nuclei with an odd mass number, I is half-integral (1 2, 3 2, 5 2, ..., 
e.g. H! , C!" , N!" , Na!"  and P!" ). 
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2. For nuclei with even mass and atomic numbers, I is zero (e.g. C!" , O!"  
and S!" ). 
3. For nuclei with an even mass and an odd atomic numbers, I is an 
integral number (1, 2, 3, ... e.g. H!  and N!" ). 
In order to be NMR active, a nucleus must have I > 0, since nuclei with zero 
nuclear spin do not interact with magnetic fields. However, many other 
factors, which will be further discussed bellow, influence the NMR signal. 
 
 
Figure 3 - Bulk magnetization (a) in the absence and (b) in the presence of an 
external magnetic field. In the absence of an external magnetic field (𝐁𝟎), the 
nuclear magnetic moments are oriented randomly, while in the presence of 𝐁𝟎 the 
nuclear magnetic moments get aligned to it, in respect to their discrete energetic 
sublevels. Figure taken from Kunz (2010). 
 
2.1.2. Magnetization 
 
In the absence of an external magnetic field, the magnetic moment of 
a NMR active nucleus is oriented randomly (Figure 3.(a)). When a static 
magnetic field B! oriented along z, by convention, is applied, its interaction 
with the nuclear magnetic moment will create a magnetic energy, E, given by: 
   
 E = −µμ ∙ B! = −µμ ∙ cos θ ∙ B! = −µμ! ∙ B! (2.5) 
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The projection of the nuclear magnetic moment in the z direction, µμ!, is given 
by the association of Equations (2.1) and (2.2). The combination of the 
classical description of the magnetic energy [Equation (2.5)] with the 
quantum mechanical formulation of the nuclear magnetic moment 
[Equations (2.1) and (2.2)] gives: 
   
 E = −γ ∙ h2π ∙m ∙ B! (2.6) 
   
Since m is a discrete quantum number, the energy levels are also 
quantized. For a particle of spin I = 1 2, two distinct energy levels associated 
with different electronic states are possible: m = 1 2 and m = − 1 2. While the 
former corresponds to a lower energy level (α spin state) where the nuclear 
magnetic moments are parallel with B!, the latter is associated with a higher 
energy level (β spin state) and the spins have an antiparallel alignment with B! (Figure 3.(b)). The energy difference between the two states is given by: 
   
 ΔE = γ h2π B! (2.7) 
   
and corresponds to electromagnetic radiation in the radio frequency (RF) 
range. The interaction between atoms and electromagnetic radiation is 
characterized by the absorption and emission of photons, such that the 
energy of the photons exactly matches an energy level difference in the atom. 
Therefore, the transition between two spin states can be achieved by applying 
an external oscillating magnetic field perpendicular to µμ! with a frequency ν, 
such that the energy carried by the photon of this magnetic field corresponds 
to the energy splitting between the two spin states: 
   
 ΔE = hν⇔ ν = γ2πB! (2.8) 
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 The induced energy level difference of nuclei in an external magnetic 
field is very small when compared with the thermal energy, making it that the 
levels are almost equally populated at room or body temperature. The ratio of 
the α and β spin states at any specific temperature T in kelvin and in the 
presence of a static magnetic field due to their difference in energy levels ΔE 
is given by: 
   
 n!n! = e! !!!!! = e! !!!!"!!! (2.9) 
   
where κ! is the Boltzmann constant. 
 As mentioned before, each nucleus can be seen as a minute bar magnet 
and, therefore, is associated with a magnetic dipole moment µμ. When placed 
in an external magnetic field B!, the nuclear magnetic moment will feel a 
torque given by: 
   
 τ = µμ×B! (2.10) 
   
According to Newton’s second law for rotations: 
   
 τ = dLdt  (2.11) 
   
The combination of the Equations (2.1), (2.10) and (2.11) originates: 
   
 dµμdt = µμ×γB! (2.12) 
   
Since the amplitude of µμ is constant, the differential equation in Equation 
(2.12) expresses the fact that µμ changes its orientation relative to B!, i.e. µμ 
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precesses about B! at a frequency ω!, named Larmor frequency and defined 
as: 
   
 ω! = γB! (2.13) 
   
The total net magnetic moment, i.e. the magnetization M , of a 
macroscopic sample is the resultant of the sum over all individual nuclear 
magnetic moments µμ!: 
   
 M = µμ!!!!!  (2.14) 
   
	  
Figure 4 - Distribution of the individual magnetic dipole moments of a population 
of identical nuclei with spin ½ in an external magnetic field (𝐁𝟎). The nuclear 
magnetic moments are divided in two populations that precess on a cone around 𝐁𝟎. 
Their vector sum results in a net macroscopic magnetization (𝐌𝟎) aligned along 𝐁𝟎. 
Figure taken from Lanz (2012). 	  
Due to quantization of the nuclear magnetic moment [see Equations 
(2.2) and (2.3)], each individual spin is oriented according to θ, the angle 
between µμ and B! . In the general case of a spin I nucleus, the magnetic 
moments will be randomly distributed on 2I+ I cones at discrete angles θ. In 
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that sense, there will be no net component of M! in the transverse xy plane, 
given that M!  is the macroscopic magnetization vector at thermal 
equilibrium. However, due to the spin state population difference, there will 
be a net component of M! parallel with B! (Figure 4) with magnitude: 
   
 M! = n! − n! ∙ µμ! (2.15) 
   
Since at normal temperature ΔE ≪ κ!T, the exponent in Equation (2.9) can be 
simplified through an expansion and truncation of a Taylor series to give: 
   
 n!n! = 1− ΔEκ!T  (2.16) 
   
Assuming n = n! + n! and n! ≈ n! ≈ !! where n is the total number of nuclear 
spins in the macroscopic sample, the population difference n! − n!  is 
approximately given by: 
   
 n! − n! ≈ nΔE2κ!T  (2.17) 
   
The association of Equations (2.7), (2.15) and (2.17) gives, at thermal 
equilibrium, the amplitude of the macroscopic magnetization vector M!: 
   
 M! = hµμ!4πκ!T γB!n (2.18) 
   
The intensity of the final received signal is proportional to the spin state 
population difference and, thus, to the amplitude of the macroscopic 
magnetization vector. The small energy level difference between the two spin 
states makes NMR, on the one hand, an insensitive technique and, on the 
other, a noninvasive and nondestructive technique, ideally suited for in vivo 
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measurements, since only non-ionizing electromagnetic fields are involved. 
However, the experiment sensitivity is determined by other factors, some of 
which can be deduced from Equation (2.18). Firstly, one can mention the 
intrinsic properties of the chosen nuclei, essentially the natural abundance 
and gyromagnetic ratio γ. In that sense, the proton nucleus (1H) is the most 
commonly used nuclei as it yields the strongest NMR signal due to a 
combination of its high natural abundance (99.98%) and high intrinsic NMR 
sensitivity (high gyromagnetic ratio γ: 42.58 MHz ∙ T!!). Additionally, the 
linear dependence of M! on the magnetic field strength B! implies that higher 
magnetic fields improve the sensitivity, and the inverse proportionality of M! 
to the temperature T indicates that sensitivity can be enhanced at lower 
sample temperatures. Obviously, the latter option is unrealistic for in vivo 
applications, which results in a constant interest in building higher magnetic 
field systems. 
 
2.1.3. Excitation 
 
 
Figure 5 - Excitation of the magnetization (A) in the laboratory frame and (B) in the 
rotating frame of reference. Using an additional oscillating magnetic field (𝐁𝟏 𝐭 ), 
the macroscopic magnetization can be tilted towards the transverse plane while it 
simultaneously precesses around the static magnetic field (𝐁𝟎 ) and 𝐁𝟏 𝐭 . The 
problem can be analyzed in a simpler way in the rotating frame, which spins about z 
at the Larmor frequency and where the macroscopic magnetization simply rotates 
about 𝐁𝟏. In the rotating frame, 𝐁𝟏 𝐭  appears static since it oscillates at the same 
frequency as the frame rotates. Figure taken from Lanz (2012). 
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The quantum mechanical representation is convenient to illustrate the 
spin distribution, but it is not very suitable to illustrate the interaction of the 
spins with external magnetic fields. Therefore, the classical picture of the net 
macroscopic magnetization M will be used in further discussions. 
The signal detection in NMR is based in the Faraday’s law of 
electromagnetic induction stipulating that a time-varying magnetic field can 
induce and electromotive force (emf) in a receiver coil surrounding the 
sample. Therefore, in order to obtain a signal, a precessional motion of the 
macroscopic magnetization needs to be detected. However, at thermal 
equilibrium, the spins have no phase coherence in the transverse plane and 
the net longitudinal magnetization is a static vector. Nuclear magnetization 
can only be observed by rotating the net longitudinal magnetization towards 
or onto the transverse plane. As mentioned before, the resonance 
phenomenon in NMR is achieved by applying an oscillating magnetic field, B! t , in the transverse plane with a frequency ν, such that the energy equals 
the energy splitting between the two spin states. From Equations (2.8) and 
(2.13) one can deduce that ν corresponds to the Larmor frequency (ν = ν!), 
which is the one required to excite spins from the α state to the β one. B! t  is 
applied as a RF pulse, i.e. turned on for a finite time and turned off again and, 
with a sinc shape, since it has the interesting property of presenting an 
excitation profile close to an ideal square function. The receiver coil, also 
called RF coil, can also be used as transmitter during the excitation process to 
generate the B! t  magnetic field. It has two effects on the spins: firstly, the 
two spin states become more equally populated as a 90° nutation (rotation) is 
approached; and secondly the spins come into a state of phase coherence, i.e. 
the B! t  magnetic field forces the phases of the spins to attain coherence 
thereby generating transverse magnetization. 
The expression of motion for a single nuclear magnetic moment 
[Equation (2.12)] can be generalized for the total magnetization, originating: 
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 dM tdt = M t ×γB t  (2.19) 
   
the so-called Larmor equation, where B t  may include time-varying 
components in addition to the static magnetic field B!. At thermodynamic 
equilibrium, B t = B!  and, therefore, !!!!" = 0  since M!  is parallel to B! . 
However, during the RF pulse, B t = B! + B! t , thus giving: 
   
 dM tdt = M t ×γ B! + B! t  (2.20) 
 
As a result, the initially longitudinal magnetization experiences a torque 
from the applied perpendicular B! t  field, which results in the precession of M t  around both B!  and B! t  progressively tilting towards the transverse 
plane (Figure 5.A). 
 Until this point, the NMR experiment has been described in a 
Cartesian frame fixed with respect to the laboratory, i.e. the “laboratory” 
frame. However, in order to simplify the description of motion of the 
magnetization vector, one must introduce the rotating frame. The rotating 
frame consists in a new set of Cartesian axes that rotates about the static 
magnetic field B! with frequency ω. The z and z’ axes of the laboratory and 
rotating frames, respectively, are collinear with the external magnetic field B!. The conversion to a rotating frame of reference has consequences for the 
magnetic field vectors encountered in that frame. Firstly, the precessional 
motion of the magnetization ω! appears to be reduced to a value (ω! −ω). It 
is convenient to define an effective magnetic field, B!"" , since the 
magnetization precesses about the effective field: 
   
 B!"" t = B! t + ω! −ωγ e! (2.21) 
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On-resonance, i.e. when the frequency of the applied RF pulse, ω!", equals 
the Larmor frequency ω!, Equation (2.21) reduces to B!"" t = B! t  and the 
magnetization simply rotates about B! t . In a frame that rotates with a 
frequency equal to the frequency of B! t , B! t  appears static (B!) (Figure 
5.B). The extent to which M  is rotated, which can be described by the 
nutation angle, θ, depends directly on the duration, τ, and amplitude of B!: 
   
 θ τ = γB!τ (2.22) 
   
When B!  is applied long enough, M  can be completely excited onto the 
transverse plane or even inverted to the –z’-axis, giving rise to so-called 90° 
excitation and 180° inversion RF pulses, respectively. The longitudinal and 
transverse magnetizations in the rotating frame can be respectively written 
regarding θ as such: 
   
 M! = M! cos θ (2.23) 
   
 M!" = M! sin θ (2.24) 
 
2.1.4. Relaxation 
 
Relaxation is the process of return to thermal equilibrium after a 
perturbation. Components of the magnetization (M!, M! and M!) return to 
the equilibrium, a process described by: 
   
 dM! tdt = −M! tT!  (2.25) 
   
 dM! tdt = −M! tT!  (2.26) 
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 dM! tdt = −M! t −M!T!  (2.27) 
   
where T! and T! are relaxation time constants; after a 90° excitation pulse, T! 
corresponds to the time at which 63% of M! relaxed back and T! to the time at 
which 37% of M!" decayed.  As mentioned before, the equilibrium state is 
defined by two conditions: the population ratio should satisfy the Boltzmann 
distribution [Equation (2.9)] and the entropy should be on its maximum, 
which corresponds to a system with no phase coherence. Therefore, two 
spontaneous processes are involved in the exponential return to equilibrium: 
the longitudinal or spin-lattice relaxation, characterized by the time constant T!; and the transverse or spin-spin relaxation, characterized by the time 
constant T!. These relaxation processes are, respectively, described by: 
   
 M! t = M! ∙ 1− e! !!! +M! 0 e! !!! (2.28) 
 M!" t = M!" 0 e! !!! (2.29) 
   
While the former describes the return of longitudinal magnetization after a 
perturbation, the latter describes the disappearance of transverse 
magnetization. Longitudinal relaxation is in principle a process in which 
energy from the spins is transferred to the surrounding molecular 
environment, called the “lattice”, and during T! relaxation spins exchange 
energy between themselves. NMR relaxation mechanisms differ from 
interactions between other electromagnetic fields and matter, as there is no 
spontaneous emission of energy to the environment. The spin relaxation 
processes can only occur through a stimulated transition by a magnetic field 
that fluctuates in a broad range of frequencies that contains the Larmor 
frequency, which is the driving frequency for stimulating an energy state 
transition. The longitudinal relaxation is induced by random fluctuating 
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fields due to thermal energy-induced motion of the molecules in the 
environment of the nuclear spin. The sources of this fluctuating magnetic 
field are dipolar coupling between nuclei and interaction between nuclear 
magnetic dipoles. Besides being also influenced by fluctuating magnetic 
fields, the transverse relaxation is affected by a static magnetic contribution, 
which is caused by the imperfect homogeneity of the applied magnetic field B!  on a molecular level. Therefore, these T!  relaxation mechanisms are 
combined with the effect of macroscopic B! inhomogeneity, resulting in a 
total decay of transverse magnetization with a time constant T!∗, which is 
always shorter than T! . Consequently, the individual nuclear spins 
accumulate progressively different phases and the coherence of the 
detectable transverse magnetization is lost. 
 
2.1.5. Bloch Equations 
 
Bloch equations provide a classical approach to describe the evolution 
of the macroscopic magnetization in the presence of an external magnetic 
field, i.e. under precession, excitation and relaxation. 
The expansion of Equation (2.20) gives: 
   
 dM! tdt = γ M! t B! −M! t B!"  (2.30) 
   
 dM! tdt = γ M! t B!" −M! t B!  (2.31) 
   
 dM! tdt = γ M! t B!" −M! t B!"  (2.32) 
   
that in combination with Equations (2.25)-(2.27) yields Bloch equations in 
the laboratory frame of reference: 
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 dM! tdt = γ M! t B! −M! t B!" −M! tT!  (2.33) 
   
 dM! tdt = γ M! t B!" −M! t B! −M! tT!  (2.34) 
   
 dM! tdt = γ M! t B!" −M! t B!" −M! t −M!T!  (2.35) 
   
In a rotating reference frame, Bloch equations can be written as: 
   
 dM!!dt = ω! −ω ∙M!! t − γM!! t B!"! −M!! tT!∗  (2.36) 
   
 dM!!dt = − ω! −ω ∙M!! t + γM!! t B!"! −M!! tT!∗  (2.37) 
   
 dM!!dt = γ M!! t B!"! −M!! t B!"! − M!! t −M!T!  (2.38) 
   
where B!"!  and B!"!  correspond to the fixed coordinates of the B! field in the 
rotating frame of reference. 
 
 
2.2. Magnetic Resonance Imaging (MRI) 
 
Magnetic resonance imaging (MRI) is, nowadays, an important 
imaging modality, since it allows the noninvasive and nondestructive 
generation of images in intact living objects. By taking advantage of the 
dissimilar NMR relaxation properties between different tissues and, thereby, 
choosing proper experimental parameters, excellent soft tissue contrast can 
be achieved. This allows the identification of spatial boundaries and 
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distribution of different tissues within the object under investigation. Besides 
the contrast between tissues, two other factors determine the quality and 
clarity of images: the signal-to-noise ratio (SNR), i.e. the signal intensity 
divided by the background noise, and the spatial resolution. In the setting of 
MRS, MRI is particularly useful for the accurate determination of the origin of 
the MRS signals taking into account that, for in vivo MRS studies, it is often of 
interest to obtain information on a specific region of the tissue, known as 
volume of interest (VOI). The principles underlying MRI also apply for many 
in vivo MRS techniques. 
 
2.2.1. Magnetic Field Gradients 	  	  
 
Figure 6 – Gradients’ system. The three set of coils generate orthogonal linear 
gradients linearly varying with the position according to (A) z, (B) y and (C) x axes. 
The magnetic field strength of all gradients is zero in the magnet’s isocenter. 
According to each direction, a gradient is progressively added or subtracted from the 
main magnetic field on each side of the middle. Figure taken from Kunz (2010). 
 
The essential concept of MRI is that the resonant frequency ω! is 
made position-dependent, such that after Fourier transformation the 
different frequencies correspond to different spatial positions. This can be 
achieved by using a third static but spatially varying magnetic field, known as 
gradient, in addition to the main field B!, thus generating a total magnetic 
field at position r given by: 
   
A	   B	  
	  
C	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 B r = B! + G! ∙ r (2.39) 
   
where G! is the gradient strength. The magnetic field gradient system is made 
up of three resistive coils that generate orthogonal magnetic fields, G!, G! 
and G!, with intensity linearly varying according to x, y and z directions, 
respectively. As a consequence, if a linear term G! ∙ r is added to B!, which 
always remains in the z direction, the resonant frequency will be linearly 
proportional to the position along r and is given by: 
   
 ω r = γ(B! + G! ∙ r) (2.40) 
   
The magnetic field gradient is positioned around the center of the 
magnet, i.e. a gradient adds to the main magnetic field on one side of the 
middle and subtracts from the static field in the other side. Therefore, the 
magnetic field strength of all gradients is zero in the magnet’s isocenter 
(Figure 6). 
Besides its linearity in space, important characteristics of a gradient 
system are its maximal strength and the minimum time needed to reach the 
maximum amplitude (i.e. rise time). The gradients strength is the main 
constraint for the spatial maximal resolution, while the rise time constrains 
the acquisition speed. 
 
2.2.2. Slice Selection 
 
To obtain an image of a 3D object, all three dimensions need to be 
encoded independently, which could be a time-consuming procedure. 
Therefore, one often reduces the problem to two dimensions by selecting a 
spatial slice out of a 3D object. 
If a magnetic field gradient is applied during the RF pulse, the 
frequency of the RF pulse can be chosen in order to be in resonance 
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conditions only for the magnetization located at a chosen position r . 
Thereby, a slice perpendicular to the gradient direction will be selected, with 
its position given by the center frequency of the RF pulse, ω!", and with a 
thickness dependent on both bandwidth of the pulse and gradient strength 
(Figure 7), according to the following relationship: 
   
 Δr = Δωγ ∙ G! (2.41) 
 
 
Figure 7 - Principle of NMR localization by slice selection. Using an additional 
gradient magnetic field, the Larmor frequency of a given nucleus becomes space-
dependent along the direction of the gradient (z in the example). A radio frequency 
(RF) pulse with a carrier frequency 𝛚𝐑𝐅 and a bandwidth Δ∆ω enables the selective 
excitation of the magnetization in a slice located at a desired position and with a 
specific thickness. Figure taken from Lanz (2012). 
 
After selecting one or more spatial slices, the origin of the MR signal 
needs to be encoded in two dimensions, i.e. individualized into pixels. 
Therefore, two more gradients must be applied to encode frequency and 
phase. In a transverse slice, the horizontal axis is usually set as the frequency 
encoding direction, while the vertical axis is the phase encoding direction of 
excited protons. These gradients (G! and G!, respectively) are required to be 
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applied at different times, since they cannot be differentiated from one 
another if they overlap. 
 
2.2.3. Frequency Encoding 
 
The frequency encoding gradient, or readout gradient, is composed of 
two constant amplitude gradient pulses. One is applied prior to signal 
acquisition (prephasing gradient) while the other, being of opposite sign and 
typically having twice the area, is applied during the signal acquisition. The 
function of the prephasing gradient is to prepare the transverse 
magnetization for encoding spatial information during signal acquisition. At 
the end of it, the transverse magnetization at each position x is prepared with 
a specific phase shift given by: 
   
 ϕ x, t = γxG!t (2.42) 
   
The second gradient pulse is of opposite sign and the total area is twice that 
of the first gradient. Therefore, the total applied gradient in the middle of the 
second gradient is zero and the dephasing caused by the initial gradient is 
completely undone. Since the transverse magnetization prior to signal 
acquisition had acquired a linear position-dependent phase shift during the 
first gradient, spins at different spatial positions have to rotate at different 
frequencies to fulfill the condition ϕ x = 0 in the middle of the second 
gradient. 
 
2.2.4. Phase Encoding 
 
The principle of phase encoding is not much different from frequency 
encoding, i.e. the magnetic field gradient G!  encodes the phase of the 
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transverse magnetization as a function of position, and indirectly the 
frequency, since: 
   
 ω y = dϕ y, tdt  (2.43) 
   
To obtain spatial information along the phase encoding dimension, a number 
of experiments need to be performed in which the amplitude of the gradient G! , usually applied before G! , is changed between +G!,!"#  and −G!,!"#  in 
fixed steps. 
 
2.2.5. Spatial Frequency Space (k-space) 
 
During the data acquisition of an MRI sequence, the transversal 
components of the magnetization in the imaging object after excitation are 
sampled from the receiver coil signal, i.e. are acquired analog and converted 
to a digital value. So far, the NMR signal has been described as a continuous, 
analog signal. Since many mathematical operations are most conveniently 
performed by digital computer algorithms, the digital signal is obtained by 
measuring the instantaneous value of the analog signal at equal time 
intervals.  The raw data is then stored in a matrix, the k-space, as a function 
of time. Each of the data points is characterized by a k! and k! value, the k-
parameters of frequency and phase-encoding directions, respectively, which 
are defined as following: 
   
 k! = γG!Δt (2.44) 
   
 k! = γG!τ (2.45) 
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where Δt is the sampling time and τ is the duration of G!. Therefore, the 
position in k-space is directly related to the gradient across the object being 
imaged. By using G! and G! sequentially, keeping the magnitude G! the same 
but changing G!’s magnitude repeatedly at each repetition time (TR) interval, 
every line of the k-space must be filled in order to generate an optimum 
image. When the phase-encoding gradient is zero, the signal gives the spatial 
distribution of the object in the x direction. 
The relationship between k-space data and image data is the Fourier 
transformation. Every point in the k-space contains part of the information 
for the complete image. However, a point in the k-space does not correspond 
to a point in the image matrix. While coordinates at the edges of the k-space 
- high spatial frequencies - provide information regarding the borders and 
contours of the image, i.e. the detail of the structures, coordinates near the 
middle of the matrix - low spatial frequencies - provide information on the 
general contrast of the image. The raw data from the MRI acquisition 
undergoes a 2D Fourier transformation, resulting in a representation of the 
magnetization amplitude distribution. Knowledge of the gradient strengths 
allows, in conjunction with Equation (2.40), the conversion of the frequency 
axes into spatial axes. 
As mentioned before, the spatial information is primarily acquired as 
an analog time-dependent signal. This signal is termed echo; gradient-echo 
and spin-echo form the basis for the majority of MRI methods.  The time 
between the slice selective RF pulse and the top of the echo, where optimum 
refocusing occurs, is referred to as echo time (TE). 
 
2.2.6. Gradient Echo 
 
An excitation pulse, i.e. a 90° RF pulse, followed by phase and 
frequency encoding, creates a gradient echo, which contributes to a line of k-
space data. The gradient echo is formed when the transverse magnetization 
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signal is at a maximum, i.e. when the area under the second frequency 
encoding gradient pulse equals the one under the prephasing gradient. Due 
to the RF pulse between 0 and 90°, part or all the magnetization is in the 
transverse plane. The frequency encoding gradient causes, in a first stage, 
different sets of spins to acquire different phases; this dephasing is, however, 
reversed at a second stage, where spins return to their original phase-
coherent state, thus forming the gradient echo (Figure 8). 
 
 
Figure 8 - (A) Gradient echo pulse sequence and (B) representation of its effect on 
macroscopic magnetization. A small flip angle β radio frequency (RF)-pulse is 
applied and, at the same time, a slice selection gradient (GSS) is used to excite only a 
slice of the sample. At the end of the slice selective gradient, the signal through the 
slice thickness is slightly dephased. To compensate for this effect, a second gradient 
is applied along the same axis, with opposite polarity and half of the area, which 
result in complete rephasing of the signal. This is followed by the application of 
phase encoding gradients (GPE). Finally the echo is generated by a fast dephasing and 
rephasing of the signal by the application of two gradients with opposite polarity 
(GRO). At the time that the second gradient has completely compensated the first 
dephasing gradient, the echo is at its maximum amplitude, decaying exponentially 
afterwards with a time constant 𝐓𝟐∗. Figure taken from Kunz (2010). 
 
It is always possible to recover a dephased signal by applying a 
magnetic field gradient of opposite sign, provided that the signal has not 
A	  
B	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been irreversibly lost by T! relaxation. The gradient reversal in gradient-echo 
techniques refocuses only those spins that have been dephased by the action 
of the gradient itself; therefore, the relaxation due to T! relaxation and static 
field inhomogeneities is not reversed and the loss of signal results from T!∗ 
effects. These sequences are, thus, more sensitive to magnetic field 
inhomogeneities, leading to an additional phase evolution that is 
independent of the applied magnetic field gradients. On the other hand, 
gradient echo techniques offer the advantage of low-flip angle excitations, 
contributing to a faster acquisition and, therefore, decreased duration of 
scan. A flip angle lower that 90° decreases the amount of magnetization 
tipped into the transverse plane, thus inducing a faster recovery of 
longitudinal magnetization. 
 
 
 
Figure 9 - (A) Spin echo radio frequency (RF) pulses and (B) representation of its 
effects on macroscopic magnetization. A 90° RF pulse is applied and flips the 
magnetization to the xy-plane, which starts to dephase with a time constant 𝐓𝟐∗. The 
application of an inversion pulse after a delay TE/2 rotates the magnetization 
around the y’-axis, refocusing the spins and generating an echo after a delay TE/2. 
Even the relaxation due to fixed causes is reversed and the loss of signal results 
uniquely from 𝐓𝟐 effects. TE: echo time. Figure taken from Kunz (2010). 	  	    
A	  
B	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2.2.7. Spin Echo 
 
Unlike gradient echo sequences, spin echo sequences allow the 
separation of the contribution of T!  and magnetic field inhomogeneity 
through the application of a 180° refocusing pulse. Briefly, an initial 90° RF 
pulse is applied, after which magnetization starts to loose coherence through T!∗ spin relaxation. After the delay TE/2, a 180° RF pulse is applied to the 
sample, which causes magnetization vector to rotate about y by 180°. 
Therefore, although spins continue to dephase, rotating at their local Larmor 
frequencies, after the 180° inverting pulse, instead of spreading further apart, 
they move closer together, being refocused along the y’-axis at the end of the 
second TE/2 delay to form a spin echo. During the inversion pulse, the slice 
selection gradient is repeated, improving the localization of the signal. 
Furthermore, since the refocusing pulse is applied, the second frequency 
encoding gradient pulse is of the same polarity as the prephasing gradient. At 
the top of the echo, the effects of the B! magnetic field inhomogeneities are 
refocused and the signal decrease is caused exclusively by inherent T! 
relaxation (Figure 9). 
 
2.2.8. Rapid Acquisition with Relaxation Enhancement 
(RARE) 
 
Through a standard fast imaging sequence - rapid acquisition with 
relaxation enhancement (RARE) - images can be acquired by exciting spins 
and refocusing the spins repeatedly with 180° pulses to give a series of 
independently phase-encoded spin echoes. Thereby, every single excitation 
pulse allows the acquisition of several lines of k-space. As expected, the 
signal strength decreases as the transverse magnetization decays (Figure 10); 
still, it represents a fast imaging technique producing high quality T! -
weighted images. 
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Figure 10 - Fast spin echo, an example of a rapid acquisition with relaxation 
enhancement (RARE) sequence. It is based on a spin echo sequence and starts with a 
90° excitation pulse together with a slice selective gradient (GSS). It allows the 
acquisition of multiple spatially encoded echoes through the sequentially 
application of inversion pulses. Obviously, the magnetization decays with 𝐓𝟐 and so 
the amplitude of echoes, but this operation can be repeated as long as the echo 
amplitude is above the noise level. Figure taken from Kunz (2010). 
 
 
2.3. 1H MRS 
 
Since nearly all metabolites contain protons, in vivo H!  MRS is in 
principle a powerful technique to observe, identify and quantify a large 
number of biologically important compounds in intact tissues. The detection 
and quantification of a wide range of metabolites has led to the 
characterization of disease progression, allows the study of intervention by 
medication or surgery and identification or categorization of diseases by 
observing specific metabolic markers. 
Up to now, it was assumed that the macroscopic magnetization was 
the sum of a population of spins having all the same resonant frequency. 
Following the Equation (2.13), nuclei of the same element (or isotope) even 
in different molecules, would resonate at the same frequency because of their 
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identical gyromagnetic ratio γ. Fortunately, however, besides depending on 
the gyromagnetic ratio γ and the external magnetic field B!, the resonant 
frequency ω! is also highly sensitive to the chemical environment of the 
nucleus under investigation. This is commonly referred to as the chemical 
shift and can be used as a fingerprint to identify molecules. 
 
2.3.1. Chemical Shift 
 
 The phenomenon of chemical shift is caused by the partial shielding of 
nuclei from the external magnetic field by electrons surrounding them. When 
placed in an external magnetic field, the electrons will rotate about B! in an 
opposite sense to the proton spin precession. Since this movement of 
electrons involves motion of charge, there will be an associated magnetic 
moment µμ! that opposes the primary applied magnetic field B! (Figure 11). 
Therefore, the electrons will reduce the magnetic field that is sensed by the 
nucleus, which can be expressed in terms of an effective magnetic field B! at 
the nucleus: 
   
 B! = B!(1− σ) (2.46) 
   
where σ is the shielding constant depending on the chemical environment of 
the nucleus. Thus, the Larmor frequency of a shielded nucleus is given by: 
   
 ω! = γB!(1− σ) (2.47) 
   
Because every chemically different nucleus has a different electronic 
environment, each one will resonate at a slightly different frequency. The 
Fourier transform of the echo gives a representation of the signal in the 
frequency domain (spectrum of resonances) and its result can be 
approximated by a Lorentzian lineshape centered at each resonant frequency 
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and with area under the peak proportional to the spins population. Usually, 
there is more than one hydrogen atom in a different chemical environment in 
a compound of interest. This leads to more than one resonance per 
compound. 
 Chemical shifts are expressed in parts per million (ppm), given that 
the differences in resonant frequency due to the chemical shift are usually 
small. Besides, expressing chemical shifts in ppm makes them independent of 
the strength of the magnetic field B!  applied and, therefore, comparable 
between different NMR instruments. The chemical shift δ is defined as: 
   
 δ = ν− ν!"#ν!"# ×10! (2.48) 
   
where ν and ν!"# are the resonant frequencies of, respectively, the compound 
under investigation and a reference compound, typically tetramethylsilane 
(TMS) for H!  MRS to which δ = 0  has been assigned. The reference 
compound should ideally be chemically inert and its chemical shift should be 
independent of external variables, such as temperature, and should produce a 
strong resonance signal well separated from all other resonances. 
 
 
Figure 11 - Origin of the chemical shift. The electrons surrounding a nucleus can be 
regarded as small currents, giving rise to a magnetic moment 𝛍𝐞 at the nucleus. 
Since the magnetic moment opposes the external magnetic field, the effective 
magnetic field at the nucleus is reduced, thereby leading to different Larmor 
frequency and hence a different chemical shift. Figure taken from de Graaf (2008). 
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2.3.2. Spin-Spin Coupling 
 
 Some resonances, on closer inspection, can be seen as one lineshape 
consisting of more than one peak. Besides being influenced by its own 
microscopic environment, i.e. the electrons around it, the nuclear spin is also 
affected by the surrounding nuclear spins. Spin-spin coupling originates from 
the fact that nuclei with magnetic moments can influence each other, besides 
directly through space (dipolar coupling) also through electrons in chemical 
bonds (scalar coupling). On a liquid environment, the dipolar coupling is 
canceled out due to the rapid molecular tumbling. However, the interactions 
through the electrons that form chemical bonds do not average to zero and 
give rise to the phenomenon of scalar coupling or, also termed, J-coupling. 
J-coupling can be understood as a chain reaction from one nuclear to 
the next in a bonded network. The electrons taking part in the covalent bond 
propagate the influence of one nuclear spin on another. However, equivalent 
nuclei, i.e. nuclei having the same physical and chemical attributes cause no 
interaction with one another and, therefore, no J-coupling effects are 
observed. Let us consider two covalently bonded nuclei A and X with a 
nuclear spin ½  resonating at a frequency ν!  and ν! , respectively. The 
electrons in this bond have to be antiparallel to one another according to the 
Pauli exclusion principle, which states that two identical fermions cannot 
occupy simultaneously the same quantum state. In addition, electrons in the 
s orbitals have a high probability of being close to the nucleus, with which 
they interact through the so-called Fermi contact interaction. This 
interaction energetically favors the antiparallel over the parallel arrangement 
of nuclear and electronic spins. However, nuclear spins can arrange 
themselves in any of these four combinations of spins states: αα, αβ, βα and 
ββ, where αα and ββ represent, respectively, the parallel and antiparallel 
alignment of both nuclear spins with the external magnetic field B!. These 
two states become energetically less favorable, since the two bonding 
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electrons cannot be both antiparallel to the nuclear spins (Figure 12.A). As a 
result for the nucleus A, the state (up or down) of the nucleus X influences its 
magnetic energy levels by splitting each of them into two, giving rise to two 
different transition energies Δ∆ E between the states up and down of the 
nuclear spin A. This is reflected in the spectrum by a splitting of the 
resonance of the nucleus A into two lines, a doublet, centered at the resonant 
frequency of the nucleus A, ν!, and separated by the characteristic coupling 
constant between nuclei A and X, J!" , which is expressed in hertz and 
determines the strength of the force exerted in a interaction. The same 
process takes place for the nucleus X (Figure 12.B). The intensity of the two 
peaks of the doublet is equal in the case of a weakly coupled system, which is 
defined as: 
   
 ν! − ν! ≫ J!" (2.49) 
   
 When more nuclei are coupled to each other through J-coupling, more 
complex patterns will appear. Depending on the magnetic equivalence of the 
coupled nuclei, the coupling can give rise to triplets, quadruplets or doublet 
of doublet patterns. Take for example a spin system comprising three non-
equivalent nuclei, A, M and X, which have a large difference in resonant 
frequency between one another. The patterns of the nucleus A and X are only 
affected by M and, so, each pattern consists of a doublet whose peaks are split 
by J!" and J!", respectively. On the other hand, M is affected by both A and 
X, originating a pattern split into four peaks of equal intensity, termed a 
doublet-of-doublets. 
The total area of all the multiplets of a given resonance is proportional 
to the magnetization of the corresponding nucleus and, thus, to its 
concentration. However, the application of H!  MRS to intact tissues is 
challenging for a number of reasons. Firstly, the water resonance is several 
orders of magnitude larger than the low concentration metabolites, making 
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metabolite detection difficult and ambiguous. Secondly, other large signals 
like extracranial lipids can also overwhelm small metabolite signal and 
thirdly, heterogeneous magnetic field distributions significantly decrease the 
spectral resolution. 
 
 
 
Figure 12 - J-coupling interaction between neighboring nuclei. (A) Representation 
of the αα state between two non-equivalent nuclei, A and X, with the respective 
nuclear and electronic arrangement. Figure taken from Lanz (2012). (B) (a) Nucleus 
in absence of a static magnetic field (𝐁𝟎). (b) Nucleus in the presence of 𝐁𝟎 magnetic 
field. (c) Two unbounded non-equivalent nuclei, A and X, in the presence of 𝐁𝟎 
magnetic field, characterized by two transition frequencies pertaining to changing of 
the spin state of either A or X. (d) The same two nuclei experiencing J-coupling due 
to chemical bonding, characterized by four separate transition frequencies, where 
each of two previous transition frequencies have been increased and decreased by a 
value of ½JAX. JAX: coupling constant between A and X. Figure taken from Kunz 
(2010). 
 
A	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2.3.3. MRS Experimental Design 
 
These previously mentioned obstacles in obtaining a spectrum of 
quality can be minimized by integrating water suppression, localization and 
shimming routines in the MRS experiment before the acquisition of the 
signal. 
 
 
Figure 13 - (A) FASTMAP (fast automatic shimming technique by mapping along 
projections) pulse sequence and (B) correspondent column selection and frequency 
encoding. It starts with a non-selective 90° radio frequency (RF)-pulse, followed by 
two slice selection pulses. It results in the selection of a column, which is spatially 
encoded with a frequency gradient along its height. The measurement is repeated by 
adding a delay τ during the first TE/2 period. The phase difference between the two 
obtained signals is then estimated, providing a mapping of the static magnetic field 
(𝐁𝟎) inhomogeneities along the column. TE: echo time. Figure taken from Kunz 
(2010). 	  
2.3.3.1. Active Shimming 
 
 Shimming is an essential step in a MRS experiment and is designed to 
provide an optimal B!  homogeneity in the VOI, making it possible to 
A	  
B	  
	   63	  
investigate spectral fine in vivo structures, such as J-coupling splitting or 
resolving overlapping of adjacent resonances. 
To correct for B! inhomogeneities, a magnetic field mapping is first 
required, based on which a calculation of the needed corrections and 
application of the estimated currents in the shim coils to generate the desired 
magnetic field can be made. The B! inhomogeneities minimization procedure 
is usually performed by fully automated, iterative methods based on 
quantitative magnetic field maps. FASTMAP (fast automatic shimming 
technique by mapping along projections) (Gruetter, 1993) is based on the 
notion that once the magnetic field is decomposed in spherical harmonics, 
mapping the effective field along six directions is sufficient to have an 
accurate estimation of the correction to apply in the entire VOI. Therefore, 
FASTMAP is a time-efficient shimming routine since it reduces the 
acquisition of a complete image of the external magnetic field B!  to 
projections acquired along a set of noncollinear axes. The technique maps the 
effective magnetic field along a column of the sample by acquiring two times 
the same projection with the acquisition delayed by a time τ in the second 
acquisition (Figure 13). The delay added during the second acquisition results 
in a phase difference between the two signals that is proportional to the B! 
inhomogeneities. 
 
2.3.3.2. Water suppression and Outer Volume 
Suppression (OVS) 
 
In vivo MRS is a very challenging technique that is designed to quantify 
metabolite signals that are 10 000-fold smaller and overlapping that of water. 
In addition, the signal should be localized in a region 100-fold smaller than 
the sample size. Therefore, most of the signal generated during the 
experiment is unwanted and must be suppressed to provide a good SNR and 
avoid contamination from outer volume signals. 
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Figure 14 - Principle of variable power RF pulses with optimized relaxation delays 
(VAPOR) water suppression. (A) The specific radio frequency (RF) pulse and delay 
combination used in VAPOR leads to a water suppression largely independent of the 
nutation angle α. (B) Longitudinal magnetization (𝐌𝐙) trajectory for 𝛂 = 𝟕𝟎°, 90° 
and 110° are shown 𝐓𝟏 = 𝟏𝟓𝟎𝟎  𝐦𝐬  and all end up close to zero at the end of the 
sequence. Figure taken from de Graaf (2008). 	  
 
Figure 15 - OVS (outer volume suppression) localization on NMR spectroscopy. (A) 
The NMR signal is localized by successive excitations and dephasing of the 
magnetization in slices surrounding the VOI. (B) Each slice is selected with the 
gradient 𝐆𝟏 and spoiled with the gradient 𝐆𝟐. Figure taken from Lanz (2012). 
 
Water is the most abundant compound in mammalian tissue and, as 
result, the proton NMR spectrum of almost all tissues is dominated by a 
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resonance at circa 4.7 ppm originating from the two protons of water. VAPOR 
(variable power RF pulses with optimized relaxation delays) is a water 
suppression technique designed to minimize sensitivity to B! 
inhomogeneities. In addition, VAPOR is insensitive towards variations in T! 
relaxation. It consists of seven frequency selective RF pulses interspersed 
with optimized T!  recovery delays. For a nutation angle α of 90°, the 
longitudinal magnetization of water prior to nonselective excitation ends up 
very close to zero despite the presence of T! relaxation. And even when the 
nutation angle is not calibrated correctly, the magnetization ends up close to 
zero due to the optimized pulse and delay combination (Figure 14). 
 Outer volume suppression (OVS) is an example of destructive 
localization. Prior to spectrum acquisition, a series of slice selective RF pulses 
excite narrow slices situated around the desired VOI, using an appropriate 
gradient for the slice selection. Following each slice-selective excitation, the 
transverse magnetization is dephased (“spoiled”) by a subsequent magnetic 
field crusher gradient (Figure 15). The result of this dephasing is a zero net 
magnetization in the corresponding slices. 
This technique is versatile, as the selected suppression bands can be 
rotated, shifted and changed in size arbitrarily by adapting the excitation RF 
pulse and gradient. However, it is limited by the T!  recovery of the 
magnetization in the different slices before the actual acquisition sequence 
starts. OVS is often used in combination with other localization techniques. 
Localization can be achieved in two distinct ways: by leaving the 
magnetization in the VOI unperturbed during the localization procedure and 
remove the unwanted external signal (destructive localization), which is the 
case of OVS, or by selectively exciting the signal in the VOI using a successive 
excitation of three orthogonal slices which intersection corresponds to the 
VOI, so that only the magnetization in the VOI generates signal (constructive 
localization).  
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2.3.3.3. Localization – SPin ECho, full Intensity 
Acquired Localized (SPECIAL) Sequence 
 
The use of a gradient field enables a one-dimensional spatial selection, 
allowing the excitation of the magnetizations located in a sample slice. 
Constructive localized spectroscopy has been largely based on stimulated-
echo acquisition mode (STEAM) or point-resolved spectroscopy (PRESS) 
methods. However, the SPin ECho, full Intensity Acquired Localized 
(SPECIAL) spectroscopy sequence (Mlynárik et al., 2006) is associated with 
improved localization performance and sensitivity. When used at high 
magnetic field strength with ultra-short TEs and sufficiently good shimming, 
approximately 21 metabolites can be detected and quantified accurately. 
High magnetic field affords increased intrinsic SNR (increased sensitivity), 
chemical shift dispersion (increased spectral resolution) and decreased strong 
coupling effects; it is useful for low concentration metabolites, strongly 
overlapped metabolites and for metabolites having complex multiplet 
patterns, leading to an improved quantification precision and accuracy. The 
ultra-short TE ensures the obtention of high quality spectra, with resolved 
lines of many metabolites due to minimal phase distortions of multiplets of 
coupled spin systems, and the minimization of signal loss due to T! 
relaxation, thus increasing the amount of biochemical information and 
contributing to a more precise quantification. In addition, acquisitions with a 
long TR minimize T! relaxation (Cudalbu, 2013). 
The SPECIAL sequence (Figure 16) is based on a combination of the 1D 
image-selected in vivo spectroscopy (ISIS) technique and a slice-selective a 
spin-echo sequence.  
The three-dimensional (3D) ISIS localization method employs three 
frequency-selective inversion pulses in the presence of three orthogonal 
magnetic field gradients. The inversion pulses are turned on or off according 
to a specific encoding scheme. For one-dimensional (1D) ISIS localization, 
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two experiments are required: one with and one without a spatially selective 
inversion pulse prior to excitation. Subtraction of the two datasets will only 
give signal from the localized volume. When zero or an even number of 180° 
pulses are executed, the desired magnetization in the cross-section of the 
three selected slices ends up along the positive longitudinal axis and 
following a 90°!! excitation pulse will end up along the positive y’-axis. 
During a scan with an odd number of 180° pulses, the desired magnetization 
ends up along the negative longitudinal axis and is excited to the negative y’-
axis by a 90°!! pulse. Adding and subtracting the individually stored scans 
with even and odd number of 180° pulses, respectively, will constructively 
accumulate signal from the desired location while destructively canceling 
signal from all other locations. 
 
 
Figure 16 - SPin ECho, full Intensity Acquired Localized (SPECIAL) sequence, water 
suppression and outer volume suppression (OVS), followed by the one-dimensional 
(1D) image-selected in vivo spectroscopy (ISIS) consisting of a 180° pulse that is 
turned on and off according to a defined scheme. A second water suppression 
module (WS) then precedes the excitation and is followed by the Spin Echo (90 and 
180° RF pulses) and finally the acquisition (Acq). Figure taken from Mlynárik et al. 
(2006). 	  
The SPECIAL sequence uses a 2-ms slice-selective adiabatic 180° pulse 
in the y-direction in alternate scans, followed by a spoiling gradient to 
remove the potential transverse magnetization. Then a spin echo sequence is 
	  68	  
applied using 0.5-ms 90° excitation and 1ms 180° inversion asymmetric slice-
selective pulses in the x and z directions. Water signal suppression is 
accomplished by a series of seven 25-ms asymmetric VAPOR that are 
interleaved with OVS consisting of three modules of 1.2-ms adiabatic pulses. 
To further improve the efficiency of water suppression, another 15-ms 
Gaussian frequency-selective saturation pulse is added in the delay between 
the adiabatic slice-selective inversion pulse and the spin echo modules. 
 
Figure 17 - 𝐇𝟏  NMR spectrum of the brain cortex of a rat acquired with SPECIAL 
(𝐓𝐄 = 𝟐.𝟖  𝐦𝐬). Figure taken from Kunz (2010). NAA: N-acetyl aspartate; Ins: myo-
inositol; PE: phosphorylethanolamine; PCr: phosphocreatine; Cr: creatine; Glc: D-
glucose; GSH: glutathione; Glu: glutamate; Gln: glutamine; Tau: taurine; GPC: 
glycerophosphorylcholine; PCho: phosphorylcholine; Asp: aspartate; GABA: γ-
aminobutyric acid; NAAG: N-acetylaspartylglutamate; Ala: alanine; Lac: lactate; 
Mac: macromolecules. 
 
2.3.4. Metabolites and Biochemistry 
 
Advances in MRS have made it possible to obtain, with continual 
improvements in resolution, non-invasive information about the 
biochemistry of the human brain. The resulting magnetic resonance 
spectrum is derived from a mixture of compounds (Figure 17), being of 
interest in the context of this thesis, the ones involved on osmoregulation, 
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neurotransmission, and antioxidant and energy metabolisms. However, the 
biochemical relationships that underlie changes in brain metabolites are fully 
interconnected and complex and, therefore, there are multiple possible 
causes for this modifications. 
 
2.3.4.1. Osmoregulation 
 
2.3.4.1.1. Choline-containing Compounds 
(Total Choline, tCho) 
 
tCho give rise to a strong singlet resonance at 3.2 ppm originating 
from nine equivalent methyl protons, which contains contributions from free 
choline, glycerophosphorylcholine (GPC) and phosphorylcholine (PC, PCho). 
Small resonance differences between the compounds can be observed 
between 3.5 ppm and 4.3 ppm arising from the methylene protons signal (de 
Graaf, 2008).  
Uptake of choline from extracellular fluids is essential, since brain 
cannot synthetize choline de novo. Choline is transported through the BBB 
by a carrier-mediated process that is unsaturated at physiological levels and 
is hence sensitive to alterations in plasma choline. In mammals, new choline 
is mostly produced by the liver, although it can be also supplied by the diet 
(Rae, 2014). 
Requirement for choline is especially high under conditions of high 
growth, mainly during the development, such that choline supply affects 
brain development and is required for normal development of memory (Rae, 
2014). 
Correlations have been reported between the tCho resonance and 
brain function, namely in abstinent alcoholics, taking into account that the 
increase in tCho resonance correlated positively with mental performance, 
probably due to previous dietary deficiencies (Rae, 2014). Decreased choline 
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signals are further associated with liver disease. Choline-containing 
compounds are involved in pathways of phospholipid synthesis and 
degradation, thereby reflecting membrane turnover (de Graaf, 2008). 
 
2.3.4.1.2. Cr 
 
The H!  NMR spectra of Cr and its phosphorylated product PCr, 
together often referred to as “total creatine”, are very similar. While their 
methyl protons produce an undistinguishable singlet resonance at 3.03 ppm, 
the difference between the Cr (3.913 ppm) and PCr (3.930 ppm) methylene 
singlet resonances is large enough to separate the two compounds at 
magnetic fields equal or higher than 7T (de Graaf, 2008). 
Cr and PCr are interconverted by the enzyme CK in reactions catalyzed 
in both mitochondria and cytosol by appropriate isoforms of the enzyme and 
through the use of ATP or adenosine diphosphate (ADP)+ H! , depending on 
the direction of the reaction. Cr in the body is derived both from diet, being 
present exclusively in meat, and from synthesis. The brain is capable of 
synthetizing Cr and the two main enzymes are present in neurons and glia. 
As mentioned in Chapter 1, Cr enters the brain via a Na+-dependent 
transporter, SLC6A8, which also allows the passage of the precursor of Cr, 
guanidinoacetate. The regional distribution of Cr and of the Cr transporter 
follows the expression of CK, which is highest in areas of highest synaptic 
activity (Rae, 2014). 
As also mentioned in Chapter 1, there is evidence for low Cr levels to 
play a role in HE. In fact, besides its energetic role, Cr acts as an organic 
osmolyte in the brain, serving a more dominant role as the brain matures. In 
addition, supplementation with Cr in rats is associated with an increase in 
the brain Ins signal, probably because of increased water retention. Besides, 
the many reported cognitive and neuroprotective effects of Cr may be related 
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with the neuronal activity modulation by acting at receptors, namely the 
NMDA and GABA ones (Rae, 2014). 
 
2.3.4.1.3. Glutamine (Gln) 
 
As mentioned in Chapter 1, Gln (2-amino-4-carbamoylbutanoic acid) 
markedly increases during hyperammonemia and, under those conditions, 
brain Gln is a good indicator of the liver disease HE. Gln is an amino acid 
present in relatively high concentrations in the brain and cerebrospinal fluid. 
Besides its previously addressed major role in the brain as a by-product of Glu 
neurotransmission, Gln is the main source of carbon backbone for synthesis 
of GABA (Rae, 2014). 
Gln is structurally similar to Glu, resulting in similar chemical shifts 
and scalar coupling interactions represented by a methine proton resonance 
triplet at 3.76 ppm and multiplets between 2.12 ppm and 2.46 ppm, 
corresponding to the four-methylene protons resonance. In order to 
understand the important roles of Glu and Gln in intermediary metabolism, 
the separate detection of these compounds is essential and has been greatly 
benefited by the increase in magnetic field strength (de Graaf, 2008). 
 
2.3.4.1.4. Myo-Inositol (Ins) 
 
Ins is by far the most prevalent isomer of hexahydroxycyclohexane, 
comprising 95% of inositols in the human body. It is acquired both by 
synthesis (mainly in the kidney) and by ingestion, although it can be derived 
by de novo synthesis from Glc in the brain. It crosses the BBB by simple 
diffusion and by a stereospecific, saturable transport system. In cultured cells 
and immortal cell lines, the level of Ins in astrocytes is higher than in 
neurons. Ins is a cyclic sugar alcohol, constituent of phosphoglycerides and 
hence lipid component of biomembranes. Additionally, it is the major 
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component of intracellular second messenger system and an organic 
osmolyte, involved in the maintenance of cell volume. Dietary 
supplementation with inositol has been used to treat a range of psychiatric 
and behavioral conditions, although the precise mechanism of action remains 
undetermined (Rae, 2014). Altered levels of Ins have been encountered in 
patients with mild cognitive impairment and Alzheimer disease, and brain 
injury (de Graaf, 2008). 
Ins contains six NMR detectable methine protons that give rise to four 
groups of resonances: a doublet-of-doublets centered at 3.52 ppm and 
triplets at 3.27 ppm, 3.61 ppm and 4.05 ppm (de Graaf, 2008). 
 
2.3.4.1.5. Taurine (Tau) 
 
The exact function of Tau is not known, but it has been proposed as an 
osmoregulator and a modulator of neurotransmitter action. Tau is present in 
all cells of the CNS, but is spatially heterogeneous, with higher levels in the 
olfactory bulb, retina and cerebellum. Its concentration is age-dependent, 
since it decreases from birth to adulthood. It is largely obtained through food, 
but it is an amino acid and it can be synthetized from other sulfur-containing 
amino acids (de Graaf, 2008). 
At higher magnetic fields Tau gives two triplets centered at 3.25 and 
3.42 ppm arising from the two methylene groups with non-equivalent 
protons (de Graaf, 2008).	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2.3.4.2. Neurotransmission 
 
2.3.4.2.1. Aspartate (Asp) 
 
Asp is an amino acid that acts as an excitatory neurotransmitter. It 
does not cross the BBB, but is instead synthetized from Glc and possibly other 
precursors (de Graaf, 2008). 
While the methine group gives a doublet-of-doublets at 3.89 ppm, the 
methylene group protons originate a pair of doublet-of-doublets at 2.65 and 
2.80 ppm (de Graaf, 2008). 
 
2.3.4.2.2. Glu 
 
Glu (2-aminopentanedioic acid) is an amino acid present in the brain 
in relatively high concentrations and with multiple roles in vivo. Glu is the 
major excitatory neurotransmitter in mammalian brain. The central role of 
Glu in the Glu-Gln neurotransmitter cycle was previously addressed in 
Chapter 1. Glu has four major subtypes of neurotransmitter receptor: three 
ionotropic receptors named after the compounds originally used selectively 
to activate them (NMDA, AMPA and Kainate) and mGluR, some of which 
previously mentioned as treatment targets in HE (see Treatment Options for 
HE in Chapter 1). Furthermore, Glu is the direct precursor for the major 
inhibitory neurotransmitter, GABA, and is also an important component in 
the synthesis of other small metabolites (e.g. the redox peptide GSH), as well 
as larger peptides and proteins. Glu can be neurotoxic, mostly through its 
actions at NMDA receptors, where it can cause mitochondrial apoptosis 
through the release of Ca2+ (Rae, 2014). 
Glu has a complex NMR spectrum with signal spread out over many 
low intensity resonances, with a doublet-of-doublets at 3.75 ppm, which 
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arises from the methine proton signal, and multiplets between 2.04 and 2.35 
ppm, conferred by the two methylene protons resonances (de Graaf, 2008). 
 
2.3.4.3. Energy Metabolism 
 
2.3.4.3.1. Alanine (Ala) 
 
Ala is an amino acid, and its concentration is found increased 
following ischemia (de Graaf, 2008). In fact, Ala and pyruvate are 
interchangeable by a transamination reaction, thus linking Ala to metabolic 
pathways, such glycolysis and gluconeogenesis. It also arises together with 
Lac in muscles during periods of decreased oxygen, and passes to the liver 
where it generates Glc from protein via the Ala cycle. 
Its spectrum of resonances presents a doublet resonance at 1.47 ppm 
and a quartet at 3.78 ppm, both arising from the coupling of the three methyl 
protons to a single methine proton (de Graaf, 2008). 
 
2.3.4.3.2. Cr and Phosphocreatine (PCr) (see 
above) 
 
2.3.4.3.3. Lactate (Lac) 
 
Lactic acid (2-hydroxypropanoic acid) exists mainly in anionic form 
(Lac) in vivo. It is the end-product of anaerobic glycolysis and is synthetized 
from pyruvate by the enzyme lactate dehydrogenase (Rae, 2014). Although it 
is normally present at low concentration, increased Lac concentrations have 
been observed under a wide variety of conditions in which blood flow (and 
hence oxygen supply) is restricted such as ischemic stroke and hypoxia. 
Transient increases in Lac levels have also been observed in human brain 
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during and following functional activation and hyperventilation (de Graaf, 
2008). 
Its spectrum resembles the Ala one, since the three equivalent methyl 
protons give rise to a doublet resonance at 1.31 ppm, while the single 
methine proton resonates as a quartet at 4.10 ppm (de Graaf, 2008). 
 
2.3.4.4. Antioxidant Metabolism 
 
2.3.4.4.1. Ascorbate (Asc) 
 
Ascorbic acid (vitamin C) occurs physiologically as the Asc anion, a 
water-soluble antioxidant that is found throughout the body with the highest 
concentration and retention capacities in the brain, spinal cord and adrenal 
glands. Asc is heterogeneously distributed throughout the brain with higher 
concentrations in the cortex and hippocampus as compared with brain stem 
and spinal cord and is present in both neurons and astrocytes. It takes part in 
the intracellular antioxidant network and has neuroprotective properties (de 
Graaf, 2008). 
The obtained spectrum yields a doublet at 4.49 ppm arising from a 
methine proton resonance, and multiplet resonances at 4.00 ppm and 3.73 
ppm, associated, respectively, a methine and methylene protons (de Graaf, 
2008). 
 
2.3.4.4.2. Glutathione (GSH) 
 
GSH (ι-γ-glutamyl-ι-cysteinylglycine) is a tripetide consisting of 
glycine, cysteine and Glu, and found ubiquitously throughout the body and in 
relatively high concentrations in the brain, as well as in the extracellular and 
cerebrospinal fluid. It can exist in reduced (GSH) or oxidized (glutathione 
disulfide, GSSG) forms and the rate GSH/GSSG is a useful indicator of the 
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cellular redox status. Astrocytes generally have higher GSH concentrations 
than neurons, although levels in some neurons are compatible with glia (Rae, 
2014). GSH is an antioxidant, essential for maintaining normal red blood cell 
structure and keeping hemoglobin in the ferrous state. Other functions 
include that of an amino acid transport system, as well as storage form of 
cysteine (de Graaf, 2008). Furthermore, GSH depletion results in 
mitochondrial dysfunction and its levels decline with age. 
It is problematic to measure in vivo concentration of GSH due to 
significant resonance overlap with other metabolites, which happens even at 
higher magnetic fields. However, it can be achieved through spectral editing 
methods. The spin system is characterized by a singlet resonance at 3.77 ppm 
derived from the methylene protons of the glycine moiety, which overlap 
with a doublet-of-doublets from the methine proton of the Glu moiety; 
multiplets at circa 2.15 and 2.55 ppm and three doublet-of-doublets at 2.93, 
2.98 and 4.56 ppm (de Graaf, 2008). 
 
2.3.5. Spectral Quantification 
 
Spectra obtained by NMR spectroscopy can, in principle, be used to 
derive absolute concentrations in animal and human tissues in vivo. This 
originates from the fact that the thermal equilibrium magnetization M! is 
directly proportional to the number of spins n, according to Equation (2.18), 
which is proportional to the molar concentration. 
There are numerous algorithms used for spectral quantification; 
however, in the context of this thesis, the explanation will be confined to the 
linear combination of model spectra of metabolites (LCModel) (Provencher, 
2001), an iterative, user-dependent model fitting algorithm imposing various 
amounts of prior knowledge. 
LCModel analyses MRS data in the frequency domain, taking into 
account that the total NMR signal obtained from a mixture of compounds can 
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be seen as a linear combination of the NMR signals from the pure or isolated 
compounds. Thereby, a basis set, composed by the metabolites spectral 
pattern, is provided as an input to LCModel. Afterwards, LCModel essentially 
adjust the amplitudes, frequencies, line widths and phases of the metabolite 
basis set to match the in vivo NMR spectrum as close as possible. The 
algorithm also imposes many soft constraints on the fitting parameters in 
order to achieve faster convergence. Most important is that the basis set is 
complete, i.e. all metabolites that are present in the in vivo NMR spectrum 
should be included in the basis set. Furthermore, the basis set should be 
acquired or quantum mechanically simulated under the same exact 
conditions as the data were, namely at the same magnetic field and with the 
same sequence and acquisition parameters. 
The resonance area of a metabolite resonance is, in principle, 
proportional to the concentration, which makes the application of a reference 
compound with known concentration a convenient method of quantification. 
For H!  MRS, water is often used as an internal reference, since its 
concentration in various part of the body is well documented. Therefore, a 
second spectrum containing the resonance of the calibration compound, i.e. 
possibly unsuppressed water, from the same VOI has to be acquired. Thereby, 
the resonance areas in the acquired spectrum are compared with that of a 
stable endogenous reference compound, by previously knowing its 
concentration. 
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CHAPTER 3  
Materials and Methods 
 
 
3.1. Aim 
 
The aim of this thesis is to elucidate, separately, the protective effects 
of two promising therapeutic agents for CHE – VSL#3® and Cr – in BDL rats. 
For that purpose, in vivo metabolic effects on osmoregulation, 
neurotransmitter, and antioxidant and energy metabolisms using 1H MRS 
were non-invasively and longitudinally analyzed. 
 
 
3.2. Rationale 
 
There is robust evidence for the pathogenesis of HE to be linked to 
alterations in gut microbiota and to be accompanied by a Cr deficiency. MRS 
techniques allow the investigation of the chronological involvement of 
metabolic events during the progression of CLD. Additionally, the use of in 
vivo, non-invasive and longitudinal magnetic resonance measurements is a 
promising tool for assessing the effects of treatments in CLD-induced HE 
without influencing it. This unique approach allows assessing in vivo and 
longitudinally the effects of VSL#3® and Cr on osmoregulation, 
neurotransmitters, and antioxidant and energy metabolisms, thereby 
opening new perspectives to offer appropriate treatments in HE. 
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3.3. Animals, Bile Duct Ligation and Treatment 
 
All experimental procedures were performed according to both local 
and federal guidelines. Fourteen adult male Wistar rats (Charles River, 
France) were kept under a 12h light-dark cycle, with food (KLIBA NAFAG, 
Provimi Kliba AG, Kaiseraugst, Switzerland) and water provided ad libitum 
before the beginning of the treatment and afterwards. 
The rats were divided into two treatment groups: VSL#3® and Cr. 
Animals treated with VSL#3® were housed individually, while the Cr treated 
ones were housed in three cages: two with two rats and one with three. To 
induce biliary cirrhosis, five animals in each of the groups underwent double 
ligation and section of the common bile duct under isoflurane anesthesia 
(Attane, Minrad, NY, USA), intubated and mechanically ventilated (2.5-4% 
isoflurane in 𝑂! and compressed air). In addition, two animals in each group 
were sham-operated. The mean body weights at the day of bile duct ligation 
were 197.3 ± 12.4 g and 199.9 ± 8.9 g for, respectively, the VSL#3® and Cr 
treated groups. The duration of the study was of eight weeks after surgery, 
after which rats were decapitated whilst anesthetized. 
 
 
3.4. VSL#3® Treatment 
 
The treatment with VSL#3® started two weeks prior the bile duct 
ligation and lasted until the end of the study, performing a total of ten weeks 
of treatment. Animals received a daily dose of VSL#3® of 50 billiards of 
bacteria/kg of body weight dissolved in water. The dose was prepared taking 
into account that a rat usually drinks 10 ml/day/100 g of body weight. The 
VSL#3® treatment was prepared freshly everyday and given to the rats in the 
evening, since they are naturally nocturnal animals. The VSL#3® solution 
intake was measured every day for each rat. 
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3.5. Cr Treatment 
 
The group treated with Cr had free access to a Cr enriched diet (KLIBA 
NAFAG, Provimi Kliba AG, Kaiseraugst, Switzerland) at a concentration of 
20g of Cr/kg of diet, which started at the bile duct ligation day and lasted 
until the end of the study, performing a total of eight weeks of treatment. The 
Cr enriched diet intake was measured once a week, per cage. 
 
 
3.6. Biochemical and Histological Measurements 
 
3.6.1. VSL#3® Treatment 
 
Blood samples were collected from the retro-orbital plexus 
immediately before the surgery and two, four, six and eight weeks after 
surgery. Immediately after the collection, blood samples were analyzed for 
bilirubin and Glc levels (Reflotron Plus, Roche, Switzerland). Afterwards, 
blood samples were centrifuged and the plasma was collected and stored at    
-80 °C for further ammonia measurements at the Laboratoire de Chimie 
Clinique (CHUV, Lausanne), by Dr. Olivier Braissant. 
Ethylenediaminetetraacetic acid (EDTA) was used as anticoagulant. 
Stool samples were collected before the beginning of the treatment 
and at the same time points as blood samples were for future measurements. 
After rats’ sacrifice, brain was extracted from the cranium and half of 
it was kept in paraformaldehyde (PFA), while the other half was stored at        
-80 °C for future histological studies in the Laboratoire de Chimie Clinique 
(CHUV, Lausanne), by Dr. Olivier Braissant. The liver was also collected, 
weighted and two samples of it stored in the same way as brains were for 
future histological studies at the same laboratory. 
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3.6.2. Cr Treatment 
 
Blood samples were collected from the sublingual vein immediately 
before the surgery and four, six and eight weeks after surgery. Immediately 
after the collection, blood samples were analyzed for bilirubin and Glc levels 
(Reflotron Plus, Roche, Switzerland). Afterwards, blood samples were 
centrifuged and the plasma was collected and stored at -80 °C for further 
ammonia measurements in the laboratory Laboratoire de Chimie Clinique 
(CHUV, Lausanne), by Dr. Olivier Braissant. EDTA was used as anticoagulant. 
After rats’ sacrifice, brain was extracted from the cranium and half of 
it kept in PFA for future histological studies in the Laboratoire de Chimie 
Clinique (CHUV, Lausanne), by Dr. Olivier Braissant. The liver was also 
collected, weighted and two samples of it kept in PFA and stored at -80 °C for 
future histological studies at the same laboratory.  
 
 
3.7. Behavioral Tests 
 
Open Field – Novel Object behavioral tests were performed at six and 
eight weeks after surgery, in the morning and at the same time, in both 
groups of treatment. For the tests, a black arena of 100-cm diameter, divided 
in inner, intermediate and outer parts was used. The boundaries of the inner 
and intermediate parts were defined at, respectively, 12.5 and 37.5-cm radius 
from the center. The inner part was illuminated with 7-9 lux, while the outer 
part was illuminated with, approximately, 2 lux less than the one used in the 
center. Before starting and between tests, arena was cleaned with 5% ethanol 
and dried. Tests were recorded through a hardware-based realtime MPEG-2 
(Moving Picture Experts Group-2) encoder secured to the ceiling above the 
center of the arena, and a frame-grabber software (MediaCruise, Canopus 
Corporation, San Jose, CA, USA). 
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The first part of the test, i.e. the open field task, had the duration of 
ten minutes and each rat was placed in the empty arena. Then, a cylindrical 
object was introduced in the center of the arena, yielding the second part of 
the test, i.e. the novel object task, which lasted five minutes. This test was 
performed to determine: (1) the distance moved, (2) the time spent under 
movement, (3) the time spent immobile, (4) the time spent in the inner part, 
(5) the time spent in the intermediate part and (6) the time spent in the outer 
part. While the first three measurements allow taking conclusions on 
locomotor activity, the last three allow the evaluation of the anxiety status. 
 
 
3.8.  In vivo  1H MRS 
 
 H!  MRS was performed before and at two, four, six and eight weeks 
after surgery on the VSL#3® treated group. In the case of the Cr treated group, 
scans were performed at four, six and eight weeks after surgery. 
The total duration of each scan per animal was approximately 1.5 
hours.  Rats were anesthetized with a dose of 4% of isoflurane and anesthesia 
was maintained between 1.5 and 2% until the end of the scan. The rat head 
was fixed in a stereotaxic system (bite bar and a pair of ear bars); then the 
animal was placed in an in-house-built holder and finally placed in the 
magnet. The vital signs of the animals were carefully monitored to provide a 
stable physiological condition. While an air pillow to monitor respiration was 
positioned under the rat, a thermosensor probe was inserted rectally. 
All in vivo H!  MRS experiments were carried out using a 9.4T MRI 
actively shielded system (horizontal bore diameter 31 cm) (Varian/Magnex, 
Palo Alto, CA). The system is equipped with an actively shielded 12-cm 
diameter high performance gradient insert (Varian/Magnex, Palo Alto, CA), 
which operates at a maximum strength of 400 mT/m, slew rate of 3000 
mT/m/ms and, therefore, taking a rise time of 130 µs to achieve the maximum 
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strength, with eddy currents after adjustment below 0.01%. The second-order 
shim strengths are on the order of 3 kHz/cm2. An home-built RF surface coil 
was used as transceiver coils, consisting of two single, 16-mm diameters, 
geometrically decoupled loops (Figure 18). 
 
 
Figure 18 - An example of a proton quadrature surface coil built in laboratory. 
 
3.8.1. Gradient Echo Sequence (GEMS) 
 
To check the position of the rat inside the magnet, i.e. if the center of 
the head is close to the isocenter of the magnet and well oriented, an ultra-
short gradient echo sequence was used. In each of three planes (axial, sagittal 
and coronal), three slices at the isocenter of the magnet were acquired. This 
sequence provides 𝑇!-weighted images, since both TR and TE are short. 
Parameters: TE/TR: 2.99/18.91 ms, Field of View (FOV): 30 × 30 mm, 
acquisition matrix: 128 × 128, 3 slices, thickness = 2 mm, gap between slices = 
2 mm, flip angle 20°. 
 
3.8.2. Fast Spin Echo Sequence (FSEMS) 
 
An FSEMS (RARE) sequence was used to provide anatomical high-
resolution 𝑇!-weighted images (long TR and TE) of the rat’s brain in order to 
observe the position of the VOI and, therefore, place the voxel correctly for 
both shimming and spectroscopy experiments (Figure 19 and Figure 20). 
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Parameters: Effective TE/TR: 52/4000 ms, FOV: 23 × 23 mm, acquisition 
matrix: 256 × 256, 15 slices, thickness = 1.0 mm, gap between slices = 0.2 mm, 
Echo train length (ETL) = 8, Echo spacing (ESP) = 13. 
 
 
Figure 19 - Screenshot of axial images acquired with fast spin echo sequence 
(FSEMS), which were used for a 2 × 2.8 × 2 mm3 voxel positioning in hippocampus. 
Parameters as in 3.8.2. 
 
 
Figure 20 - Screenshot of sagittal images acquired with fast spin echo sequence 
(FSEMS), which were used for a 2 × 2.8 × 2 mm3 voxel positioning in hippocampus. 
Parameters as in 3.8.2. 
 
3.8.3. FAST(EST)MAP 
 
A voxel of 2.5 × 3.2 × 2.5 mm3 centered in the same position as the 
acquisition voxel was shimmed beforehand. Shimming of the voxel was done 
using the FASTMAP (Gruetter, 1993) , as previously introduced in Chapter 2. 
Firstly, 𝐵! field is measured along x, y and z directions and the corrections for 
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𝐵!  inhomogeneity are made by the first order shims (linear spherical 
harmonics). The second step does the same, but measures the magnetic field 
along xy, yx, xz, zx, yz and zy directions. The third step uses FAST(EST)MAP 
(Gruetter and Tkáč, 2000), a version of FASTMAP with performance and 
speed optimized. Using an approach based on asymmetric echo-planar 
readout gradient trains, multiple echoes are formed. Thereby, for N echoes 
recorded, N-1 phase maps are extracted for each projection. The third step 
measures the same projections as step two, the corrections are made this 
time by the second order shim coils (z2, zx, zy, x2-y2, 2xy). The acquired water 
signal was used as an indicator of the 𝐵! homogeneity and was decreased as 
much as feasibly possible. 
 
3.8.4. SPECIAL Sequence 
 
SPECIAL sequence (Mlynárik et al., 2006) was used for proton 
spectroscopy, as previously introduced in Chapter 2. The voxel used to 
acquire the signal was placed in the hippocampus, a region of the brain 
associated with memory, and had a volume of 2 ×  2.8 ×  2 mm3. Parameters: 
TE/TR = 2.8/4000 ms, acquisition matrix = 256 × 128, 160 averages. 
 
 
3.9. Quantification of Brain Metabolites 
 
Quantification and computation of metabolite and macromolecular 
concentrations was performed using LCModel (Provencher, 2001), as 
previously introduced in Chapter 2. The basis set was measured in vitro using 
aqueous solutions of all metabolites and the same magnetic field, sequence, 
acquisition parameters and temperature as that in vivo. The internal reference 
used was the water signal, which was obtained during another scan 
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immediately after the acquisition of the metabolites spectrum with similar 
parameters but no water suppression. Since the concentration of water is 
known – 55 mol – as well as the percentage of tissue it makes up in the brain 
– 80% -, by comparison of the surface areas of the metabolite peaks with that 
of water, absolute concentration was achieved. Concentrations are given as 
µmol per gram of tissue. Peaks with chemical shift range between 0 and 4.3 
ppm were acquired. Also calculated are the Cramer-Rao lower bounds 
(CRLBs). These are the lowest estimator-independent errors, and provide a 
measure of the reliability of each metabolite concentration result, 
quantitatively described as such: 
for CRLB < 10% ⇒ sufficient precision; 
for CRLB < 20− 30% ⇒ consider with caution; 
for CRLB > 30% ⇒ insufficient precision. 
However, these should be taken as guideline, rather than an absolute set of 
rules, as the CRLB also increases with spectral overlap. Therefore, certain 
metabolites with similar chemical structures will always have slightly higher 
CRLBs. 
 
 
3.10. Statistical Analysis 
 
The two groups (animals treated with VSL#3® and Cr) were compared 
with previously obtained data on BDL and sham operated animals without 
any type of treatment. Sham-operated animals were used as controls in each 
group. Furthermore, individually for each rat, scans at later time points were 
compared with scan zero, i.e. the scan that took place before surgery. 
Statistical analysis was performed by student’s t-test and statistical 
significance was taken to be 𝑝 < 0.05. All data was presented as the mean ± 
standard deviation unless otherwise stated. 
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CHAPTER 4 
Results 
 
4.1. Treatment with VSL#3® 
 
4.1.1. Animal Characterization 	  
Seven adult male Wistar rats were treated with VSL#3®, five of which 
were BDL and two were sham-operated. Due to surgical complications, one 
rat died a few days after bile duct ligation. Furthermore, two rats died – one 
at seven and the other one at eight weeks after bile duct ligation, before the 
performance of the eighth MRS scan - due to cirrhotic complications. 
Table 1 and Table 2 show the animal characteristics at six and eight 
weeks after bile duct ligation, respectively. Bilirubin levels were above the 
threshold associated with liver disease after bile duct ligation (0.5 mg/dl), 
thus confirming that the bile duct was properly ligated and that no rat 
recovered afterwards. With increasing time after surgery BDL rats showed a 
longitudinal trend of decrease of body weight and an increase of liver weight 
when comparing with sham-operated rats. A similar trend of decreased 
plasma Glc was noticed, reaching statistical significance (𝑝 < 0.02) at six 
weeks after surgery. Figure 21 shows images of two livers, taken immediately 
post-mortem: one from a BDL rats and the other from a sham-operated rat. 
 
Table 1 - Characteristics of BDL and sham-operated rats treated with VSL#3®, at six 
weeks after surgery. 
 Body Weight (g) Glc (mg/dl) # Bilirubin (mg/dl) 
BDL (n=4) 316.3 ± 54.1 93.3 ± 15.8 8.5 ± 2.3 
Sham (n=2) 348.5 ± 34.6 232.5 ± 64.3 < 0.5 
# Statistically significant differences when comparing BDL and sham-operated rats 
(𝑝 < 0.02) 
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Table 2 - Characteristics of BDL and sham-operated rats treated with VSL#3®, at 
eight weeks after surgery. 
 
Body Weight 
(g) 
Glc (mg/dl) 
Bilirubin 
(mg/dl) 
Liver Weight 
(g) 
BDL (n=2) 308.0 ± 7.1 90.7 ± 24.5 5.7 ± 0.6 28.0 ± 5.7 
Sham (n=2) 369.5 ± 40.3 161.0 ± 18.4 < 0.5 10.5 ± 2.1 
 
 
   
Figure 21 - Images of the liver of (A) BDL 139 and (B) sham 143. 
It is notorious the bile pouch formed by the bile duct ligation in the first photo, and 
also the difference of color and shape between the two livers, indicative of a 
cirrhotic liver in the first case. Images are not on the same scale. 
 
4.1.2. Consumption of VSL#3® 
 
A dose of 50 billiards of bacteria per kilogram of body weight was 
dissolved in water and given to each rat every day. The solution was prepared 
taking into account that a rat consumes 10 milliliters of water per 100 grams 
of body weight per day. 
Figure 22 represents the VSL#3® solution intake per rat per day and 
Table 3 the body weight of each rat during the entire study. One can notice 
that: 
A	   B	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1) BDL 142 did not consume, on average and based on its body weight, 
the expected amount of VSL#3® solution. BDL 142 was significantly heavier 
than the other BDL and one sham-operated rats; 
2) BDL 139 significantly consumed more VSL#3® solution than the 
other BDL rats and one sham-operated rat; 
3) BDL 141 significantly consumed more VSL#3® solution than BDL 
140.  
4) BDL 140 significantly weighted less and consumed less VSL#3® 
solution than the other animals. 
No statistically significant differences were observed comparing BDL 
139 with BDL 141 and sham-operated rats concerning body weight. 
Furthermore, sham-operated group was significantly (𝑝 < 0.03) heavier than 
BDL group during the study. 
 
 
Figure 22 - Daily consumption of VSL#3® solution per rat. Bars represent de mean 
value ± standard deviation. 
* Statistically significant lower value in comparison with BDL 139 (𝒑 < 𝟎.𝟎𝟎𝟓) 
§ Statistically significant lower value in comparison with BDL 141 (𝒑 < 𝟎.𝟎𝟎𝟓) 
+ Statistically significant lower value in comparison with BDL 142 (𝒑 < 𝟎.𝟎𝟎𝟓)   
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Table 3 - Mean body weight of each VSL#3® treated rat over the entire study. 
 BDL 139 + BDL 140 * § + BDL 141 + BDL 142 Sham 143 Sham 144 + 
Body 
Weight (g)# 
259.8 ± 39.7 228.3 ± 30.4 268.4 ± 41.5 318.3 ± 63.4 307.4 ± 63.7 273.8 ± 47.0 
* Statistically significant lower value in comparison with BDL 139 (𝑝 < 0.005) 
§ Statistically significant lower value in comparison with BDL 141 (𝑝 < 0.0005) 
+ Statistically significant lower value in comparison with BDL 142 (𝑝 < 0.01 ) 
# Statistically significant differences when comparing BDL and sham-operated rats 
(𝑝 < 0.03) 
 
It is, however, important to note that animals were not weighted every 
day to minimize their stress level, contrary to the VSL#3® intake 
measurements. 
 
4.1.3. 1H MRS Data 
 H!  MRS scans were performed just before surgery and two weeks after 
the beginning of treatment (scan 0), and at two, four, six and eight weeks 
after surgery (scans 2, 4, 6 and 8, respectively) in the hippocampus. 
Therefore, besides having the sham-operated group as control at matched 
time points, each rat was also his own control by comparison with scan 0. 
Eight weeks was the determined end point, as BDL rats do not usually survive 
much longer and it was necessary to perform histology on brain and liver 
tissues taken from animals a few minutes post-mortem. 
 H!  MRS data was acquired with a sufficiently high SNR (see Table 4 
and Table 5) for the accurate detection of 21 metabolite resonances. The high 
quality data can also be observed on the spectra presented on Figure 23. 
 
Table 4 - Mean signal-to-noise ratio (SNR) of each scan on VSL#3® treated BDL rats. 
 Scan 0 (n=4) Scan 2 (n=4) Scan 4 (n=4) Scan 6 (n=4) Scan 8 (n=2) 
SNR 25.0 ± 2.9 27.3 ± 2.6 27.5 ± 3.1 28.5 ± 5.7 26.5 ± 0.7 
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Table 5 - Mean signal-to-noise ratio (SNR) of each scan on sham-operated rats 
treated with VSL#3®. 
 Scan 0 Scan 2 Scan 4 Scan 6 Scan 8 
SNR (n=2) 34.0 ± 4.2 26.5 ± 0.7 26.0 ± 0.0 22.0 ± 4.2 19.0 ± 2.8 
 
 
Figure 23 - Spectrum of metabolites of BDL 141 at (A) scan 0 and (B) scan 8. 
Spectra are of high resolution due to good quality shimming, perfect voxel 
localization (proven by the absence of lipids contamination at 0.9 ppm), good water 
suppression and baseline. 	  
 Figure 24 and Figure 25 represent the overall evolution of brain 
metabolism of, respectively, BDL and sham-operated groups treated with 
VSL#3®. 
 
Figure 24 - Longitudinal evolution of brain metabolism of all BDL rats treated with 
VSL#3® (n=4, scan 0 – scan 6; n=2, scan 8). Bars represent de mean value ± standard 
deviation. 
$ Statistically significant differences in comparison with scan 0 ( 𝒑 < 𝟎.𝟎𝟓 ) 
# Statistically significant differences when comparing BDL and sham-operated 
groups at matched time points (𝒑 < 𝟎.𝟎𝟒) 
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Figure 25 - Longitudinal evolution of brain metabolism of all sham-operated rats 
treated with VSL#3® (n=2). Bars represent de mean value ± standard deviation. 
# Statistically significant differences when comparing BDL and sham-operated 
groups at matched time points (𝒑 < 𝟎.𝟎𝟒) 	  
4.1.3.1. Osmoregulation 
 
4.1.3.1.1. Gln 
 
 Table 6 shows the Gln concentrations of each rat over the entire study. 
For the BDL group, CRLBs (the quantification errors) ranged between 2 and 
8% with a mean value of 4.5%. For the sham group, CRLBs ranged between 4 
and 8%, with a mean value of 6.1%. 
 No statistically significant differences were observed by comparison 
between BDL and sham-operated groups at matched time points; however, 
BDL rats presented, in average, 108.5 and 120.7% higher Gln concentration 
levels at, respectively, scans 6 and 8. Furthermore, a longitudinal increase of 
Gln concentration was noticed in the BDL group, with a statistically 
significant average increase of 30.2 (𝑝 < 0.02), 118.1 (𝑝 < 0.05) and 140.5% 
(𝑝 < 0.05) at, respectively, scans 2, 6 and 8 in comparison with scan 0. Within 
BDL group, BDL 139 presented the lowest concentration levels of Gln. At scan 
6, the Gln level of BDL 139 was, approximately, 2.9, 1.9 and 1.6-fold lower 
than the Gln levels of, respectively, BDL 140, 141 and 142. At scan 8, BDL 141 
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showed an approximately 2-fold higher Gln concentration level than BDL 139 
did. 
 The mean standard deviations as a percentage for each week’s average 
were 28.2 and 11.0% for, respectively, BDL and sham-operated groups. 
 
Table 6 – Glutamine (Gln) concentrations obtained per rat over the entire study. 
  
BDL 
139 
BDL 
140 
BDL 
141 
BDL 
142 
Sham 
143 
Sham 
144 
Concentration 
(µmol/g) 
Scan 0 2.80 3.20 3.20 3.31 3.42 3.00 
Scan 2 3.47 4.65 4.39 3.77 3.43 3.77 
Scan 4 3.50 7.23 5.01 4.54 3.07 3.65 
Scan 6 3.69 10.66 6.93 6.01 3.00 3.54 
Scan 8 5.04  10.01  3.04 3.77 
 
4.1.3.1.2. Ins 
 
 Table 7 shows the Ins concentration levels of each rat over the entire 
study. For the BDL group, CRLBs ranged between 3 and 5% with a mean value 
of 3.4%. For the sham group, CRLBs ranged between 2 and 4%, with a mean 
value of 2.9%. Within BDL group, a longitudinal trend of decrease of Ins over 
time was noticed, reaching statistical significance at scan 6 (𝑝 < 0.02), with 
an average decrease of 24.1% in comparison with scan 0. Moreover, the 
decrease of Ins concentration was more accentuated in BDL rats expressing 
higher concentrations of Gln, and vice-versa. 
 
Table 7 – Myo-Inositol (Ins) concentrations obtained per rat over the entire study. 
  
BDL 
139 
BDL 
140 
BDL 
141 
BDL 
142 
Sham 
143 
Sham 
144 
Concentration 
(µmol/g) 
Scan 0 6.76 6.78 7.12 7.41 6.81 6.29 
Scan 2 6.99 6.91 7.05 6.68 7.64 6.47 
Scan 4 7.68 5.53 6.64 6.95 7.81 7.35 
Scan 6 6.26 3.98 5.56 5.49 7.62 6.92 
Scan 8 6.91  3.87  8.20 6.85 
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No statistically significant differences were observed by comparison 
between BDL and sham-operated groups at matched time points; however, 
BDL rats presented, in average, 26.8 and 28.4% lower Ins concentration levels 
at, respectively, scans 6 and 8. 
The mean standard deviations as a percentage for each week’s average 
were 15.9 and 8.2% for, respectively, BDL and sham-operated groups. 
 
4.1.3.1.3. tCho (GPC + PCho) 
 
 Table 8 shows the tCho concentration levels of each rat over the entire 
study. For the BDL group, CRLBs ranged between 6 and 13% with a mean 
value of 8.9%. For the sham group, CRLBs ranged between 6 and 11%, with a 
mean value of 8.2%. 
 
Table 8 – Total choline (tCho) concentrations obtained per rat over the entire study. 
  
BDL 
139 
BDL 
140 
BDL 
141 
BDL 
142 
Sham 
143 
Sham 
144 
Concentration 
(µmol/g) 
Scan 0 0.82 0.86 0.78 0.64 0.69 0.82 
Scan 2 0.83 0.87 0.85 0.62 0.70 0.77 
Scan 4 0.90 0.73 0.68 0.63 0.79 0.85 
Scan 6 0.80 0.44 0.43 0.49 0.70 0.88 
Scan 8 0.73  0.54  0.75 0.83 
 
 
Within BDL group, tCho concentration showed a trend of decrease of 
30.2 and 18.2% at, respectively, scans 6 and 8, in comparison with scan 0. In 
the same way as the results obtained for Ins, a relation between tCho 
decrease and Gln increase was verified among BDL rats, since animals with 
higher Gln concentrations registered a more prominent decrease of tCho. 
No statistically significant differences were observed by comparison 
between BDL and sham-operated groups at matched time points; however, 
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BDL rats presented, in average, 31.6 and 19.6% lower tCho concentration 
levels at, respectively, scan 6 and scan 8. 
The mean standard deviations as a percentage for each week’s average 
were 19.2 and 9.5% for, respectively, BDL and sham-operated rats.  
 
4.1.3.1.4. Tau 
 
 No statistically significant differences were observed by comparison 
between BDL and sham-operated groups at matched time points. In fact, 
average Tau concentration values did not differ much between groups during 
the study. At scan 6 and 8, average Tau concentration levels of the BDL group 
were, respectively, 2.6 and 0.8% lower than in sham-operated group. A 
statistically significant decrease in Tau concentration levels was noticed in 
BDL group at scan 4 (𝑝 < 0.04) and scan 6 (𝑝 < 0.02) in comparison with scan 
0, which corresponded, respectively, to 11.7 and 16.5% of decrease.  
 The mean standard deviations as a percentage for each week’s average 
were 6.4 and 3.8% for, respectively, BDL and sham-operated rats. For the BDL 
group, CRLBs ranged between 3 and 4% with a mean value of 3.4%. For the 
sham group, CRLBs ranged between 3 and 4%, with a mean value of 3.7%. 
 
4.1.3.1.5. Cr 
 
When compared with sham-operated groups at matched time points 
BDL rats presented, in average, 8.4 and 10.3% lower Cr concentration values 
at, respectively, scan 6 and scan 8. However mainly due to small number of 
animals used in this pilot study, no statistically significant differences were 
observed by comparing with sham animals. In addition, a trend of decrease 
was noticed, with average decreases of 5.9 and 7.3% at, respectively, scan 6 
and 8 in comparison with scan 0.  
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The mean standard deviations as a percentage for each week’s average 
were 6.6 and 2.9% for, respectively, BDL and sham-operated groups. For the 
BDL group, CRLBs ranged between 4 and 7% with a mean value of 5.2%. For 
the sham group, CRLBs ranged between 5 and 7%, with a mean value of 5.6%. 
 
The total osmolyte concentrations comprising Gln, Ins, tCho, Tau and 
Cr were monitored over the duration of the experiment and it was found that 
their sum remained approximately constant, with a standard deviation of 2.5 
and 2.4% for BDL and sham-operated groups, respectively. 
 
4.1.3.2. Neurotransmission 
 
4.1.3.2.1. Asp 
 
No statistically significant differences were observed by comparison 
between BDL and sham-operated groups at matched time points. At scan 6, 
BDL group had a 28.2% lower Asp average concentration value in comparison 
with sham-operated group; however, at scan 8, it was 1.4% higher. In 
addition, no statistical significance was achieved when comparing the 
longitudinal evolution of Asp in the BDL group; however, a trend of decrease 
was noticed, with average decreases of 29.2 and 28.5% at, respectively, scan 6 
and 8 in comparison with scan 0. However, these results need to be handled 
with caution, since CRLBs, in the BDL group, ranged between 14.0% and 
87.0%, with a mean value of 24.3%, and in the sham-operated group, they 
ranged between 11.0 and 45.0%, having a mean value of 20.9%. 
The mean standard deviations as a percentage for each week’s average 
were 25.9 and 22.9% for, respectively, BDL and sham-operated rats. 
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4.1.3.2.2. Glu 
 
Statistically significant differences ( 𝑝 < 0.03 ) were observed by 
comparison between BDL and sham-operated groups at scan 4, where the 
BDL group presented, in average, 6% lower Glu concentration values. In 
addition, a longitudinal decrease of Glu concentration was noticed in the BDL 
group, with a statistically significant (𝑝 < 0.03) average decrease of 12.3% at 
scan 6 in comparison with scan 0. 
The mean standard deviations as a percentage for each week’s average 
were 5.7 and 3.7% for, respectively, BDL and sham-operated groups. For the 
BDL group, CRLBs ranged between 2.0 and 4.0% with a mean value of 3.0%. 
For the sham group, CRLBs ranged between 2.0 and 4.0%, with a mean value 
of 2.8%. 
 
4.1.3.3. Antioxidant Metabolism 
 
4.1.3.3.1. Asc 
 
No statistically significant differences were observed by comparison 
between BDL and sham-operated groups at matched time points, neither 
when comparing each time point with scan 0. In fact, during the progression 
of the disease, fluctuations on the levels of Asc were observed. However, 
concentration decreases were of higher magnitude and, therefore, an overall 
trend of decrease remained in the BDL group; average decreases of 19.4 and 
11.8% were obtained at, respectively, scan 6 and 8 in comparison with scan 0. 
Furthermore and in comparison with sham-operated group, BDL group 
presented an average Asc concentration 8.1% lower and 10.0% higher at, 
respectively, scans 6 and 8. 
The mean standard deviations as a percentage for each week’s average 
were 15.0% and 13.8% for, respectively, BDL and sham-operated rats. For the 
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BDL group, CRLBs ranged between 8.0 and 19.0% with a mean value of 11.0%. 
For the sham group, CRLBs ranged between 6.0 and 18.0%, with a mean value 
of 11.3%. 
 
4.1.3.3.2. GSH 
 
 A trend of increase in GSH concentrations was observed, reaching 
statistical significance at scan 4 in comparison with scan 0 (𝑝 < 0.05), with an 
average difference of 28.8%. No statistically significant differences were 
observed by comparison between BDL and sham-operated groups at matched 
time points; however and until scan 4, GSH average concentration was higher 
in BDL group, reaching 6.2% at scan 4. A drop on GSH average concentration 
in BDL group occurred between scan 4 and 6, although an overall trend of 
increase prevailed, with an average increase of 4.7 and 10.1% in comparison 
with scan 0 at, respectively, scans 6 and 8. However and in comparison with 
sham-operated group, BDL group presented, at scans 6 and 8, 4.7 and 10.1% 
lower values that were below statistical significance. 
These results need to be handled with caution, since CRLBs, in the 
BDL group, ranged between 15.0% and 32.0%, with a mean value of 21.6%, 
and in the sham-operated rats, they ranged between 13.0 and 27.0%, having a 
mean value of 20.2%. The mean standard deviations as a percentage for each 
week’s average were 22.8% and 23.7% for, respectively, BDL and sham-
operated rats. 
 
4.1.3.4. Energy Metabolism 
 
4.1.3.4.1. PCr 
 
No statistically significant differences were observed by comparison 
between BDL and sham-operated groups at matched time points; however, 
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BDL rats presented, in average, 11.0% higher and 1.4% lower PCr 
concentration values at, respectively, scan 6 and scan 8. In addition, no 
statistical significance was achieved when comparing the longitudinal 
evolution of Cr in the BDL group; however, a trend of decrease was noticed, 
with average decreases of 8.0 and 7.8% at, respectively, scan 6 and 8 in 
comparison with scan 0. Taking into account that the average PCr 
concentration remained, approximately constant from scan 6 until scan 8, 
the dissimilar average differences observed between BDL and sham-operated 
groups at scans 6 and 8 might, therefore, be due to naturally occurring 
fluctuations. 
The mean standard deviations as a percentage for each week’s average 
were 8.2% and 6.5% for, respectively, BDL and sham-operated groups. For the 
BDL group, CRLBs ranged between 4.0 and 6.0% with a mean value of 4.8%. 
For the sham group, CRLBs ranged between 4.0 and 8.0%, with a mean value 
of 5.3%. 
 
4.1.3.4.2. Ala 
 
No statistically significant differences were observed by comparison 
between BDL and sham-operated groups at matched time points; however, 
BDL rats presented, in average, 21.2 and 27.3% lower Ala concentration 
values at, respectively, scan 6 and scan 8. In addition, no statistical 
significance was achieved when comparing the longitudinal evolution of Ala 
in the BDL group; however, a trend of decrease was noticed, with average 
decreases of 44.0 and 64.8% at, respectively, scan 6 and 8 in comparison with 
scan 0. 
However, these results need to be handled with caution, since CRLBs, 
in the BDL group, ranged between 9.0% and 43.0%, with a mean value of 
23.9%, and in the sham-operated rats, they ranged between 15.0 and 37.0%, 
having a mean value of 26.1%. 
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The mean standard deviations as a percentage for each week’s average 
were 31.9% and 30.8% for, respectively, BDL and sham-operated rats. 
 
4.1.3.4.3. Lac 
 
No statistical significance was achieved when comparing the 
longitudinal evolution of Lac in the BDL group; however, a trend of decrease 
was noticed, with average decreases of 1.6 and 39.4% at, respectively, scan 6 
and 8 in comparison with scan 0. In fact, a sharp decrease of the average Lac 
concentration occurred between scans 0 and 2; from scan 2 and until scan 6, a 
progressive increase was observed, after which a sharp drop occurred 
between scan 6 and 8. In addition, no statistically significant differences were 
observed by comparison between BDL and sham-operated groups at matched 
time points; however, BDL rats presented, in average, 56.9 and 95.0% higher 
Lac concentration values at, respectively, scan 6 and scan 8. The mean 
standard deviations as a percentage for each week’s average were 48.3% and 
35.4% for, respectively, BDL and sham-operated rats. 
However, these results need to be handled with caution, since CRLBs 
(excluding those with null measured concentration), in the BDL group, 
ranged between 5.0% and 35.0%, with a mean value of 14.6%; in the sham-
operated rats, they ranged between 12.0 and 19.0%, having a mean value of 
14.3%. 
 
4.1.3.4.4. Glucose (Glc) 
 
As expected according to the longitudinal biochemical measurements 
performed in the blood, a longitudinal trend of decrease of brain Glc 
concentration was observed, reaching statistical significance at scan 6 
(𝑝 < 0.01), with an average decrease of 82.9% in comparison with scan 0. 
Furthermore and comparing with the sham-operated group, BDL group 
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significantly (𝑝 < 0.04) showed, in average, a 83.1% lower Glc concentration 
at scan 6. These results, however, were, approximately, 1.5-fold higher than 
the body blood Glc levels measured by blood sampling. Furthermore, these 
results are considered imprecise, since CRLBs (excluding those with null 
measured concentration), in the BDL group, ranged between 14.0% and 
434.0%, with a mean value of 82.8%, and in the sham-operated rats, they 
ranged between 14.0 and 55.0%, having a mean value of 25.1%. The mean 
standard deviations as a percentage for each week’s average were 85.9% and 
41.6% for, respectively, BDL and sham-operated groups. 
 
 
4.2. Treatment with Cr 
 
4.2.1. Animal Characterization 
 
Seven male Wistar rats, five of which were BDL and two were sham-
operated, were treated with Cr, starting immediately after surgery. 
 
Table 9 - Characteristics of BDL and sham-operated rats treated with Cr, at eight 
weeks after surgery. 
 
Body Weight 
(g) # 
Glc (mg/dl) # 
Bilirubin 
(mg/dl) 
Liver Weight 
(g) # 
BDL (n=5) 293.4 ± 39.9 72.2 ± 20.1 6.3 ± 0.8 28.0 ± 6.0 
Sham (n=2) 382.5 ± 7.8 188.0 ± 7.1 < 0.5 10.0 ± 0.0 
# Statistically significant differences when comparing BDL and sham-operated rats 
(𝑝 < 0.04) 
 
Table 9 shows the animal characteristics at eight weeks after bile duct 
ligation. Bilirubin levels were above the threshold associated with liver 
disease after bile duct ligation (0.5 mg/dl), thus confirming that the bile duct 
was properly ligated and that no rat recovered afterwards. With increasing 
time after surgery, BDL rats showed a longitudinal and statistically 
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significant decrease of body weight (𝑝 < 0.04) and Glc levels (𝑝 < 0.001), and 
an increase of liver weight (𝑝 < 0.01) when comparing with sham-operated 
rats at eight weeks after bile duct ligation. Figure 26 shows images of two 
livers, taken immediately post-mortem: one from a BDL rats and the other 
from a sham-operated rat. 
  
Figure 26 - Images of the liver of (A) BDL 154 and (B) sham 156. 
It is notorious the bile pouch formed by the bile duct ligation in the first photo, and 
also the difference of color and shape between the two livers, indicative of a 
cirrhotic liver in the first case. Images are not on the same scale. 
 
4.2.2. Consumption of Cr 
 
A diet enriched with a dose of 20 grams of Cr per kilogram of diet was 
given to animals. The dose was chosen taking into account that a rat 
consumes between 15 and 25 grams or 5% of its body weight per day. The diet 
intake was measured once per week per cage. BDL rats were divided in two 
cages – one with three rats (BDL 150 – 152) and the other one with two rats 
(BDL 154 and 155) – and sham-operated rats were housed together in one 
cage. 
 
A	   B	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Table 10 - Mean daily consumption of Cr enriched diet per rat, depending on its 
cage. 
 Cage 1 Cage 2 ¥ Cage 3 
Diet consumed/rat/day (g) 22.4 ± 3.9 18.0 ± 4.3 21.4 ± 1.2 
¥ Statistically significant lower value in comparison with cage 1 (𝑝 < 0.05) 
 
 
Table 11 - Mean body weight of each Cr treated rat over the entire study. 
 Cage 1 Cage 2 ¤ Cage 3 
 BDL 150 BDL 151 BDL 152 BDL 153 BDL 154 
Sham 
155 
Sham 
156 
Body 
Weight 
(g) # 
268.4 ± 
46.0 
268.3 ± 
46.1 
292.3 ± 
51.7 
242.8 ± 
37.7 
246.9 ± 
30.9 
298.4 ± 
63.0 
281.2 ± 
60.4 
¤ Statistically significant lower values in comparison with other cages (𝑝 < 0.004) 
# Statistically significant differences when comparing BDL and sham-operated rats 
(𝑝 < 0.006) 
 
Table 10 represents the daily diet consumed per rat depending on its 
cage and Table 11 shows the body weight of each rat during the entire study. 
Thereby, one can deduce that, based on their body weight, every rat 
consumed more than the expected; however, diet intake measurements were 
performed per cage and not per animal. A statistically significant (𝑝 < 0.05) 
lower consumption was verified in cage 2, in comparison with cage 1. 
Correspondingly, the average weight of animals in cage 2 was significantly 
(𝑝 < 0.0004) lower in comparison with cage 1 over the study. Furthermore, 
sham-operated group was significantly (𝑝 < 0.006) heavier than BDL group 
during the study. 
 
4.2.3. 1H MRS Data 
 H!  MRS scans were performed at four, six and eight weeks after 
surgery (scans 4, 6 and 8, respectively). Time points four and six in particular 
were chosen as these had been noticed as significant time points for sharp 
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changes in metabolite concentrations in previous studies. Eight weeks was 
the determined end point, as BDL rats do not usually survive much longer 
and it was necessary to perform histology on brain and liver tissues taken 
from animals a few minutes post-mortem. 
 
Table 12 - Mean signal-to-noise ratio (SNR) of each scan on Cr treated animals. 
 BDL (n=5) Sham (n=2) 
 Scan 4 Scan 6 Scan 8 Scan 4 Scan 6 Scan 8 
SNR 24.6 ± 1.8 24.8 ± 3.3 22.8 ± 2.6 20.5 ± 0.7 23.5 ± 3.5 22.0 ± 1.4 
 
 
 
Figure 27 - Spectrum of metabolites of BDL 151 at (A) scan 4 and (B) scan 8. 
Spectra are of high resolution due to good quality shimming, perfect voxel 
localization (proven by the absence of lipids contamination at 0.9 ppm), good water 
suppression and baseline. 	  	  
 H!  MRS data was acquired with a sufficiently high SNR (see Table 12) 
for the accurate detection of 21 metabolite resonances. The high quality data 
can also be observed on the spectra presented on Figure 27. 
Figure 28 and Figure 29 represent the overall evolution of brain 
metabolism of, respectively, BDL and sham-operated groups treated with Cr. 
A	   B	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Figure 28 - Longitudinal evolution of brain metabolism of all BDL rats treated with 
Cr (n=5). Bars represent de mean value ± standard deviation. 
★ Statistically significant differences in comparison with scan 4 ( 𝒑 < 𝟎.𝟎𝟓 ) 
# Statistically significant differences when comparing BDL and sham-operated 
groups at matched time points (𝒑 < 𝟎.𝟎𝟑) 	  
 
Figure 29 - Longitudinal evolution of brain metabolism of all sham-operated rats 
treated with Cr (n=2). Bars represent de mean value ± standard deviation. 
# Statistically significant differences when comparing BDL and sham-operated 
groups at matched time points (𝒑 < 𝟎.𝟎𝟑) 
 
4.2.3.1. Osmolytes 
 
4.2.3.1.1.Gln 
 
A statistically significant increase was longitudinally noticed in BDL 
group, reaching, in average, 27.3% (𝑝 < 0.009) at scan 6 and 86.6% (𝑝 <0.002 ) at scan 8 in comparison with scan 4. Furthermore, statistically 
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significant differences were observed by comparison between BDL and sham-
operated groups at scan 6 (𝑝 < 0.0007), where the BDL group presented, in 
average, 104.3% higher Gln concentration values; and at scan 8 (𝑝 < 0.02), 
with an average concentration 173.7% higher. 
The mean standard deviations as a percentage for each week’s average 
were 14.7% and 6.6% for, respectively, BDL and sham-operated groups. For 
the BDL group, CRLBs ranged between 2.0 and 5.0% with a mean value of 
4.0%. For the sham group, CRLBs ranged between 6.0 and 9.0%, with a mean 
value of 8.0%. 
 
4.2.3.1.2. Ins 
 
A statistically significant decrease was longitudinally noticed in BDL 
group, reaching, in average, 12.1% (𝑝 < 0.05) at scan 6 and 27.7% (𝑝 < 0.002) 
at scan 8 in comparison with scan 4. Furthermore, statistically significant 
differences were observed by comparison with sham-operated group at scan 4 
(𝑝 < 0.02), scan 6 (𝑝 < 0.02) and at scan 8 (𝑝 < 0.01), with, respectively, 
average Ins concentration values 13.7, 22.8 and 34.6% lower. 
The mean standard deviations as a percentage for each week’s average 
were 11.3% and 1.7% for, respectively, BDL and sham-operated groups. For 
the BDL group, CRLBs ranged between 3.0 and 5.0% with a mean value of 
3.7%. For the sham group, all CRLBs had a value of 3.0%. 
 
4.2.3.1.3. tCho (GPC + PCho) 
 
An overall decrease in tCho concentration levels was noticed in BDL 
group, reaching statistical significance at scan 8 (𝑝 < 0.006), with an average 
35.2% decrease in comparison with scan 4.  Still at scan 8, statistically 
significant differences were observed by comparison with sham-operated 
group (𝑝 < 0.01), with average tCho concentration 48.0% lower. 
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The mean standard deviations as a percentage for each week’s average 
were 19.7% and 7.4% for, respectively, BDL and sham-operated groups. For 
the BDL group, CRLBs ranged between 7.0 and 30.0% with a mean value of 
11.1%. For the sham group, CRLBs ranged between 7.0 and 9.0% with an 
average value of 8.0%. 
 
4.2.3.1.4. Tau 
 
No statistical significance was achieved when comparing the 
longitudinal evolution of Tau in the BDL group; in fact, only an increase of 
low magnitude was registered, with an average value of 0.5% at scan 8 in 
comparison with scan 4. Likewise, no statistically significant differences were 
observed between BDL and sham-operated groups; at scan 8, BDL group 
presented, in average, a 4.6% lower value, which seems to be related with 
naturally occurring fluctuations. 
The mean standard deviations as a percentage for each week’s average 
were 5.9% and 5.6% for, respectively, BDL and sham-operated groups. For the 
BDL group, CRLBs ranged between 3.0 and 5.0% with a mean value of 3.7%. 
For the sham group, CRLBs ranged between 3.0 and 5.0% with an average 
value of 4.0%. 
 
4.2.3.1.5. Cr 
 
 No statistical significance was achieved when comparing the 
longitudinal evolution of Cr in the BDL group, neither in comparison with 
sham-operated group at matched time points. It was registered an average 
1% increase and 3.6% decrease at, respectively, scan 6 and 8 in comparison 
with scan 4. In addition, the BDL group showed lower concentration levels of 
Cr in comparison with the sham-operated group, which were in the order of 
5.9 and 10.8% at, respectively, scan 6 and 8. A coincident statistically 
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significant 38.3% (𝑝 < 0.02) diminution on the consumption of Cr enriched 
diet in the cage 2 occurred between the sixth and eighth weeks after surgery. 
Furthermore, between the seventh and eighth weeks, cage 1 registered an 
approximate 31.1% reduced consumption in comparison with the previous 
week. 
The mean standard deviations as a percentage for each week’s average 
were 5.6 and 4.8% for, respectively, BDL and sham-operated groups. For the 
BDL group, CRLBs ranged between 5.0 and 7.0% with a mean value of 5.7%. 
For the sham group, CRLBs ranged between 4.0 and 6.0% with an average 
value of 5.3%. 
The total osmolyte concentration comprising Gln, Ins, Tau, Cr and 
tCho were monitored over the duration of the experiment and it was found 
that their sum remained roughly constant, with standard deviations of 4.0% 
for the BDL group and 1.1% for the sham-operated one. 
 
4.2.3.2. Neurotransmission 
 
4.2.3.2.1. Asp 
 
No statistical significance was achieved when comparing the 
longitudinal evolution of Asp in the BDL group, neither in comparison with 
sham-operated group at matched time points. However, a trend of decrease 
of Asp concentration was noticed in the BDL group, with a drop between 
scans 6 and 8. At scan 8, the BDL group presented a 31.8% average decrease 
in comparison with scan 4, and a 30.2% average lower value comparing with 
sham-operated group. However, these results need to be handled with 
caution, since CRLBs, in the BDL group, ranged between 17.0% and 53.0%, 
with a mean value of 27.8%, and in the sham-operated group, they ranged 
between 23.0 and 29.0%, having a mean value of 25.8%. The mean standard 
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deviations as a percentage for each week’s average were 30.5% and 10.0% for, 
respectively, BDL and sham-operated groups. 
 
4.2.3.2.2. Glu 
 
 In BDL group, a statistically significant ( 𝑝 < 0.02 ) longitudinal 
decrease of Glu concentrations, when comparing scans 4 and 8, was noticed. 
At scan 8, Glu concentrations were, in average, 13% diminished in 
comparison in scan 4. No statistically significant differences were observed 
between BDL and sham-operated groups; however, at scan 8, BDL group 
presented, in average, a 14.0% lower value. 
The mean standard deviations as a percentage for each week’s average 
were 5.8 and 2.0% for, respectively, BDL and sham-operated groups. For the 
BDL group, CRLBs ranged between 2.0 and 4.0% with a mean value of 3.1%. 
For the sham group, CRLBs ranged between 3.0 and 4.0% with an average 
value of 3.2%. 
 
4.2.3.3. Antioxidant Metabolism 
 
4.2.3.3.1. Asc 
 
 No statistical significance was achieved when comparing the 
longitudinal evolution of Asc in the BDL group; in fact, only a decrease of low 
magnitude was registered, with an average value of 2.4% at scan 8 in 
comparison with scan 4. On the other hand, statistically significant (𝑝 < 0.02) 
differences were obtained between BDL and sham-operated groups at scan 8, 
with a 19.5% lower average value in the BDL group. 
 The mean standard deviations as a percentage for each week’s average 
were 10.7 and 18.2% for, respectively, BDL and sham-operated groups. For 
the BDL group, CRLBs ranged between 10.0 and 16.0% with a mean value of 
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12.9%. For the sham group, CRLBs ranged between 10.0 and 24.0% with an 
average value of 14.2%. 
 
4.2.3.3.2. GSH 
 
No statistical significance was achieved when comparing the 
longitudinal evolution of GSH in the BDL group; however, a trend of decrease 
was noticed, reaching, in average, 19.4% at scan 8, in comparison with scan 4. 
On the other hand, statistically significant (𝑝 < 0.03 ) differences were 
obtained between BDL and sham-operated groups at scan 6, with a 41.6% 
lower average value in the BDL group. These results need, however, to be 
handled with caution, since CRLBs, in the BDL group, ranged between 16.0% 
and 58.0%, with a mean value of 28.1%, and in the sham-operated group, 
they ranged between 14.0 and 32.0%, having a mean value of 22.0%. The 
mean standard deviations as a percentage for each week’s average were 33.9% 
and 17.5% for, respectively, BDL and sham-operated groups. 
 
4.2.3.4. Energy Metabolism 
 
4.2.3.4.1. PCr 
 
Overall decreases in PCr concentration levels were noticed in BDL 
group, reaching statistical significance at scan 8 (𝑝 < 0.04), with an average 
13.6% decrease in comparison with scan 4.  Still at scan 8, statistically 
significant differences were observed by comparison with sham-operated 
group (𝑝 < 0.0005), with average tCho concentration 11.4% lower. 
The mean standard deviations as a percentage for each week’s average 
were 3.9% and 6.7% for, respectively, BDL and sham-operated groups. For the 
BDL group, CRLBs ranged between 4.0 and 7.0% with a mean value of 5.2%. 
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For the sham group, CRLBs ranged between 4.0 and 6.0% with an average 
value of 5.0%. 
 
4.2.3.4.2. Ala 
 
No statistical significance was achieved when comparing the 
longitudinal evolution of Ala in the BDL group; however, a trend of increase 
was noticed, reaching, in average, 17.0% at scan 8, in comparison with scan 4. 
In average, this increase was, however, 22.9% lower comparing with the 
sham-operated group at scan 8. These results are considered, however, 
imprecise, since CRLBs, in the BDL group, ranged between 19.0% and 101.0%, 
with a mean value of 36.5%, and in the sham-operated group (excluding 
those with null measured concentration), they ranged between 21.0 and 
31.0%, having a mean value of 26.2%. Furthermore, the mean standard 
deviations as a percentage for each week’s average were 31.1% and 51.6% for, 
respectively, BDL and sham-operated groups. 
 
4.2.3.4.3. Lac 
 
Overall increases in Lac concentration levels were noticed in BDL 
group, reaching statistical significance at scan 8 (𝑝 < 0.0004 ), with an 
average 46.6% increase in comparison with scan 4.  Still at scan 8, statistically 
significant differences were observed by comparison with sham-operated 
group (𝑝 < 0.005), with average Lac concentration 74.2% higher. These 
results need, however, to be handled with caution, since CRLBs, in the BDL 
group, ranged between 9.0% and 23.0%, with a mean value of 14.5%, and in 
the sham-operated group, they ranged between 12.0 and 27.0%, having a 
mean value of 20.8%. The mean standard deviations as a percentage for each 
week’s average were 12.6% and 29.8% for, respectively, BDL and sham-
operated groups. 
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4.2.3.4.4. Glc 
 
 As expected according to the longitudinal biochemical measurements 
performed in blood, longitudinal decreases in brain Glc concentration levels 
were noticed in BDL group, reaching statistical significance at scan 8 
(𝑝 < 0.05), with an average 68.8% decrease in comparison with scan 4.  Still at 
scan 8, statistically significant differences were observed by comparison with 
sham-operated group (𝑝 < 0.02), with average Glc concentration 79.8% lower. 
In addition, a statistically significant (𝑝 < 0.002) 64.2% lower average Glc 
concentration was obtained at scan 6, in comparison with the sham-operated 
group. These results are, however, imprecise, since CRLBs (excluding those 
with null measured concentration), in the BDL group, ranged between 29.0% 
and 160.0%, with a mean value of 59.9%, and in the sham-operated group, 
they ranged between 17.0 and 50.0%, having a mean value of 31.0%. In 
addition, these results were approximately, 1.5-fold higher than the body 
blood Glc levels measured by blood sampling. Furthermore, the mean 
standard deviations as a percentage for each week’s average were 76.7% and 
11.9% for, respectively, BDL and sham-operated groups. 
 
 
4.3. Behavioral Tests 
 
Open field-Novel object tests were performed at six and eight weeks 
after surgery, one day before the respective scan, in both groups of treatment. 
 
4.3.1. Open Field Task 
 
The results for the open field task are presented in terms of distance 
moved (Figure 30), time spent under movement (Figure 31) and percentage of 
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time spent in the inner part of the arena (Figure 32), and were compared 
between non-treated, VSL#3® and Cr treated BDL and sham-operated groups 
of animals. 
 
Figure 30 - Distance moved during the open field task of the non-treated sham 
(n=8), non-treated BDL (n=19), VSL#3®-treated sham (n=2), VSL#3®-treated BDL (n=4 
at sixth weeks after surgery; n=2 at eighth weeks after surgery), Cr-treated sham 
(n=2) and Cr-treated BDL (n=5) groups of animals, at fourth, sixth and eighth weeks 
after surgery. normal: without treatment; probiotique: treated with VSL#3®. 
 
Figure 31 - Time spent under movement during the open field task of the non-
treated sham (n=8), non-treated BDL (n=19), VSL#3®-treated sham (n=2), VSL#3®-
treated BDL (n=4 at sixth weeks after surgery; n=2 at eighth weeks after surgery), Cr-
treated sham (n=2) and Cr-treated BDL (n=5) groups of animals, at four, six and 
eight weeks after surgery. normal: without treatment; probiotique: treated with 
VSL#3®. 
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Figure 32 - Percentage of time spent in the inner part of the arena during the open 
field task of the non-treated sham (n=8), non-treated BDL (n=19), VSL#3®-treated 
sham (n=2), VSL#3®-treated BDL (n=4 at sixth weeks after surgery; n=2 at eighth 
weeks after surgery), Cr-treated sham (n=2) and Cr-treated BDL (n=5) groups of 
animals, at four, six and eight weeks after surgery. normal: without treatment; 
probiotique: treated with VSL#3®. 
 
No statistical significant differences were found between groups, 
mainly due to the small sample size in both treated groups, which 
contributed to a high standard deviation. However, one can notice a trend to 
a lower distance moved, time spent under movement and percentage of time 
spent in the center of arena in BDL groups, in comparison with its 
correspondent sham-operated groups. This was significantly confirmed, 
however, with previous results from CIBM performed in a bigger sample of 
non-treated BDL and sham-operated animals. 
 Figure 33 shows previous results on distance moved during the open 
field task at four, six and eight weeks after surgery. The BDL group presented 
a statistically significant lower distance moved in comparison with sham-
operated group, at both six (𝑝 < 0.05) and eight (𝑝 < 0.01) weeks after 
surgery.  
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Figure 33 - Distance moved during the open field task of the non-treated sham 
(n=8) and non-treated BDL (n=19) groups, at four, six and eight weeks after surgery. 
* Statistically significant differences between non-treated sham-operated and BDL 
groups at matched time points (𝒑 < 𝟎.𝟎𝟓) 
** Statistically significant differences between non-treated sham-operated and BDL 
groups at matched time points (𝒑 < 𝟎.𝟎𝟏) 	  
 Figure 34 presents previous results on time spent under movement 
and immobile during the open field task at four, six and eight weeks after 
surgery. The BDL group presented a statistically significant less time spent in 
movement and a correspondingly higher immobile time, in comparison with 
sham-operated group, at both six (𝑝 < 0.05) and eight (𝑝 < 0.001) weeks after 
surgery. 
 
 
 
Figure 34 - Time spent (A) under movement and (B) immobile during the open field 
task of the non-treated sham (n=8) and non-treated BDL (n=19) groups, at four, six 
and eight weeks after surgery. 
* Statistically significant differences between non-treated sham-operated and BDL 
groups at matched time points (𝒑 < 𝟎.𝟎𝟓) 
*** Statistically significant differences between non-treated sham-operated and BDL 
groups at matched time points (𝒑 < 𝟎.𝟎𝟎𝟏) 
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Figure 35 - Percentage of time spent in the (A) inner, (B) intermediate and (C) 
outer parts of the arena during the open field task of the non-treated sham (n=8) and 
non-treated BDL (n=19) groups, at four, six and eight weeks after surgery. 
* Statistically significant differences between non-treated sham-operated and BDL 
groups at matched time points (𝑝 < 0.05) 
 
 Figure 35 shows previous results on percentage of time spent in the 
inner, intermediate and outer parts of the arena during the open field task at 
four, six and eight weeks after surgery. The BDL group presented a 
statistically significant lower time spent in the inner and higher time spent in 
the outer parts of the arena, in comparison with sham-operated group at 
eight (𝑝 < 0.05) weeks after surgery. 
 
4.3.2. Novel Object Task 
 
 The previously obtained results with non-treated animals and under 
novel object task, in terms of distance moved (Figure 36) and time spent 
under movement and immobile (Figure 37) were, in general, similar to those 
related to the open field task. Results differed, however, in the percentage of 
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time spent in each region of the arena (Figure 38). Statistically significant 
differences between non-treated sham and BDL groups were observed six 
weeks after surgery, with the BDL spending less time in the inner and 
intermediate areas, and more time in the outer part of the arena. No 
significant differences were observed at eight weeks after surgery due to the 
learning effect; animals recognize the introduced object from previously 
performed behavioral tests and, consequently, spend less time exploring it, 
near to the center of the arena. 
 
 
Figure 36 - Distance moved during the novel object task of the non-treated sham 
(n=8) and non-treated BDL (n=19) groups, at four (1), six (2) and eight (3) weeks after 
surgery. 
** Statistically significant differences between non-treated sham-operated and BDL 
groups at matched time points (𝒑 < 𝟎.𝟎𝟏) 	  
 
 
Figure 37 - Time spent (A) under movement and (B) immobile during the novel 
object task of the non-treated sham (n=8) and non-treated BDL (n=19) groups, at 
four (1), six (2) and eight (3) weeks after surgery. 
** Statistically significant differences between non-treated sham-operated and BDL 
groups at matched time points (𝒑 < 𝟎.𝟎𝟏) 
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Figure 38 - Percentage of time spent in the (A) inner, (B) intermediate and (C) 
outer parts of the arena during the novel object task of the non-treated sham (n=8) 
and non-treated BDL (n=19) groups, at four (1), six (2) and eight (3) weeks after 
surgery. 
* Statistically significant differences between non-treated sham-operated and BDL 
groups at matched time points (𝒑 < 𝟎.𝟎𝟓) 
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CHAPTER 5 
Discussion and Conclusions 
 
 
Treatment strategies of HE over the years have been generally based 
on clinical experience, instead of scientific foundations. Therefore, efficacy 
and safety are still a matter of debate. It is, however, clear that there is not a 
miraculous cure and treatment may rely on a conjunct of agents. Among 
them, VSL#3® and Cr arose recently as promising treatment options for CHE. 
To the best of our knowledge, this is the first time that studies on 
efficacies of VSL#3® and Cr are carried out in a rat model of CHE, through a 
longitudinal study of brain metabolism. Concerning VSL#3®, only one study 
has been performed so far in BDL rats, which was confined to assessing the 
effects of VSL#3® in endothelial dysfunction (Rashid et al., 2014). Regarding 
Cr, studies have been carried out in an in vitro model of cultured embryonic 
rat brain cell aggregates (Braissant et al., 2008). Furthermore, except for 
studies carried out in CIBM/LIFMET, only one longitudinal MRS study was 
performed in BDL rats to investigate brain edema in liver failure (Chavarria et 
al., 2013). However, it was performed at lower magnetic field strength (7T), 
reporting changes in very few metabolites, and only between four and six 
weeks after bile duct ligation. 
The present thesis is, therefore, based on two pertinent and 
preliminary studies, which may contribute to the definition of a new and 
more satisfactory treatment approach in CHE. 
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5.1. 1H MRS 	  
5.1.1. Osmoregulation 
 
The present study has indicated a statistically significant increase in 
brain Gln concentration, accompanied by significant decreases (Ins and Tau 
in the VSL#3®-treated group; Ins and tCho in the Cr-treated group) and 
trends of decrease (tCho and Cr in the VSL#3®-treated group; Cr in the Cr-
treated group) in brain osmolyte concentration within BDL groups. The 
substantial increase in Gln concentration levels coupled with the constant 
total concentration of osmolytes (Gln, Tau, Ins, tCho and Cr) indicates that 
there is an osmoregulatory response proportional to the augmentation in Gln 
concentration, as expected to compensate for the osmotic imbalance induced 
by astrocytic Gln accumulation due to ammonia detoxification in these cells, 
as previously reported (Heins and Zwingmann, 2010; Cudalbu, 2013). 
Moreover, Ins seems to be the osmolyte showing the most important 
decrease as a compensatory effect for the Gln increase, which is in 
accordance with previously published data (Laubenberger et al., 1997; 
Cudalbu, 2013). 
Cr is involved in energy metabolism, but recently its involvement in 
osmoregulation and neuroprotection was reported (Braissant, 2010a). The Cr 
decrease was more evident in the VSL#3®-treated group, as expected due to 
Cr supplementation to the other group. The decrease of Cr concentration is in 
agreement with results obtained by the group of Prof. Olivier Braissant in 
brain cell 3D cultures under hypperammonemia (Braissant et al., 2008). 
 
5.1.2. Neurotransmission 
 
A statistically significant reduction in Glu concentration was observed, 
accompanied by a trend of decrease for Asp in both VSL#3® and Cr-treated 
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groups of animals. As mentioned in Chapter 1, hyperammonemia induces 
alterations in neurotransmission. Furthermore, an adequate supply of the 
neurotransmitter Glu is maintained in the CNS by the Glu – Gln cycle: Gln 
effluxes from astrocytes and enters neurons through the Gln transporter 
(SNAT) where it is hydrolyzed in mitochondria by PAG to yield Glu; Glu is 
released by neurons and taken up by astrocytes via the glutamate transporter 
(GLT-1), thus completing the cycle. This decrease observed in Glu may, 
therefore, underlie an alteration in the efflux of Gln from astrocytes, through 
a partial suppression of SNAT, as previously shown for acute HE (Kanamori 
and Ross, 2005). Moreover, chronic hyperammonemia inactivates the GLT-1 
in astrocytes (Albrecht and Jones, 1999), resulting in increased extracellular 
Glu. Collectively, these factors may interfere with Glu synthesis. 
 
5.1.3. Antioxidant Metabolism 
 
Longitudinal decreases were registered for GSH in the Cr-treated 
group and for Asc in both groups of treatment. In fact, a diminution in 
antioxidants correlates with the potential presence of oxidative stress due to 
ammonia exposure, as previously noticed ( Braissant, 2010b; Bosoi et al., 
2012).  
 
5.1.4. Energy Metabolism 
 
Statistically significant decreases of Glc were longitudinally reported 
in both groups of treatment, being in accordance with Glc measurements 
performed in blood samples throughout the study. 
Furthermore, in the VSL#3®-treated group, overall trends of decrease 
for PCr and Ala concentrations were observed; for the Cr-treated group, a 
statistically significant decrease of PCr was longitudinally noticed, 
accompanied by a statistically significant increase of Lac concentrations. 
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Accordingly, cerebral energy metabolism might be altered in chronic models 
of HE and hyperammonemia and MPT seems to play a crucial role in the 
bioenergetic failure associated with HE and hyperammonemia (Rama Rao and 
Norenberg, 2012). Further studies are needed in order to establish the 
potential role of energy dysfunction in BDL rats. 
 
This thesis relies on two pivotal studies and, therefore, they were 
designed based on a small sample of animals. The low number of sham-
operated rats underlies the lack of statistical significance that was generally 
observed when comparing BDL and sham-operated groups at later time 
points. 
In the case of the VSL#3® treated group and in addition to the small 
sample size, we had a high mortality rate  throughout the study; due to 
cirrhotic complications, we obtained a 25% mortality rate at seven weeks 
after surgery and a 50% of mortality at the eighth week in the BDL group, 
which significantly reduced the sample size. 
Moreover, high CRLBs were obtained specially for low concentrated 
and overlapping metabolite resonances. In those cases quantification is 
difficult and may lead to unexpected results, especially for small sample 
studies. Hence, future studies are needed to validate some measurements. 
 
Treatments were further compared with previously obtained results in 
BDL rats without treatment, at matched time-points. Figure 39 and Figure 40 
compare brain metabolisms of all BDL rats treated with VSL#3® and BDL rats 
without treatment at, respectively, scans 6 and 8. Figure 41 and Figure 42 
represent the same, but for the Cr-treated group. No statistically significant 
differences were obtained between treatment and no treatment groups. 
However and at scan 6, animals treated with Cr seemed to show better 
response to the treatment, represented by a slightly smaller increase in Gln, 
in comparison with non-treated animals. 
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Figure 39 - Brain metabolism comparison between all BDL rats treated with VSL#3® 
(n=4) and BDL rats without treatment (n=10) at scan 6. Bars represent de mean value 
± standard deviation. 
 
 
 
Figure 40 - Brain metabolism comparison between all BDL rats treated with VSL#3® 
(n=2) and BDL rats without treatment (n=10) at scan 8. Bars represent de mean value 
± standard deviation. 
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Figure 41 - Brain metabolism comparison between all BDL rats treated with Cr (n=5) 
and BDL rats without treatment (n=10) at scan 6. Bars represent de mean value ± 
standard deviation. 
 
 
 
Figure 42 - Brain metabolism comparison between all BDL rats treated with Cr (n=5) 
and BDL rats without treatment (n=10) at scan 8. Bars represent de mean value ± 
standard deviation. 
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5.2. Treatment with VSL#3® 
 
Due to the small number of animals in the VSL#3® treated group, no 
statistically significant difference was noticed. In addition, a big variability in 
the animals’ response to VSL#3® was noticed (i.e. the increase of Gln 
concentration ranged from 5 to 10 mmol). Therefore, for now on, we will 
discuss the results obtained at six weeks after surgery, when all the animals 
were still alive. From these data (values at six weeks after bile duct ligation) 
we can notice that BDL rats that drank more also survived longer: BDL 139 
and BDL 141. These two rats also had smaller brain Gln concentrations at six 
weeks after bile duct ligation.  We also noticed that, at the beginning of the 
treatment, animals drank slightly more than they were supposed to – the 
amount of water was supposed to be 10 ml/100 g of weight. But at the end of 
the study the animals drank only the necessary or even maybe less, based on 
their weight. This might suggest that the dose should be increased for the 
next group of rats. 
 
 
5.3. Treatment with Cr 
 
Apparently, Cr exerted a neuroprotective effect at scan 6, when the 
reported brain Gln concentrations were slightly lower than the ones obtained 
in the non-treated BDL group. However, this beneficial effect was not evident 
at scan 8. Animals consumed, in average, the Cr dose expected: between 15 
and 25 grams or 5% of its body weight per day. However, BDL animals 
coincidently reduced their diet intake from week six until the end of the 
study. This preliminary study helped us in elucidating an important number 
of issues related to the planning of the study (diet intake, etc.) and showed 
promising results related to the neuroprotective role of Cr in BDL rats, 
however the number of rats has to be increased in future experiments. 
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5.4. Behavioral Tests 
 
Due to the small sample size, we didn’t obtain statistically significant 
results with treatments, since high standard deviations were observed. 
However, from previously performed behavioral tests in a bigger sample, one 
can note a lower locomotor activity (deduced from lower distance moved and 
time spent under movement, and higher time spent immobile) and higher 
anxiety status (lower time spent in the inner part of the arena and higher 
time spent in the outer part) of BDL rats in comparison with sham-operated 
rats. 
 
 
5.5. Pinworms 
 
During these studies, an unexpected pinworm infection was detected 
in the rats of CIBM. Therefore, a post-mortem direct examination of the 
caecum and colon content, using warm saline, a technique found in literature 
(Effler et al., 2008), allowed the observation of adult pinworms in 75% of the 
rats treated with VSL#3®, and 100% treated with Cr. This might have 
influence the results obtained, since pinworms highly influence immunologic 
and nutrients absorption parameters. 
 
In conclusion, we characterized for the first time the in vivo and 
longitudinal progression of VSL#3® and Cr treatments for HE in a model of 
CLD using 𝐻!  MRS. Our preliminary results are promising, showing the 
feasibility of the study and opening the way to improve our experimental 
protocol. To increase the number of animals and the VSL#3® dose, as well as 
give the treatment through gavation to assure that all the animals consume 
the same amount are possible protocol ameliorations for future new and 
more precise measurements. 
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